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 ABSTRACT 
 
Background: 
 Spinal administration of neostigmine as a non-opioid analgesic appears 
to provide a potent, long lasting analgesia. The present study was designed to 
evaluate the effects of the addition of different doses of neostigmine on the 
characteristics of spinal anaesthesia using bupivacaine, and to assess their 
postoperative analgesic efficacy and safety in patients undergoing infra-
umbilical surgery under spinal anaesthesia.  
 
Methods: 
 In this prospective study, we studied sixty Sudanese patients, classified 
as class 1 and 2 according to the American society of anesthesiologist (ASA), 
in the age group 19 - 65 year old. They were scheduled for infra-umbilical 
surgery under spinal anaesthesia. Patients were randomly allocated to one of 
three groups (n=20 each): group one  received intrathecal bupivacaine 15 mg, 
and group two received intrathecal bupivacaine 15 mg and neostigmine 50 
µg, and group three received intrathecal bupivacaine 15 mg and neostigmine 
100µg. The onset of anaesthesia, the duration of complete postoperative 
analgesia, the time to use of the first rescue analgesics, the overall 24-h VAS 
pain scores, and the incidence of adverse effects, if any, were recorded for 24-
h post drug administration. Intraoperative and postoperative blood pressure, 
heart rate, and oxygen saturation, and total amount of analgesic consumed 
overall 24-h, were also recorded. 
 
Results: 
 Onset of anaesthesia (level to pinprick at 5 and 10 minuets) was 
significantly earlier for group 2 and 3 patients compared with group 1 
patients. Motor block (time to lift leg) was greatly prolonged for group 3 
 patients. There was a significant prolongation in the duration of absolute 
analgesia between different groups (p < 0.05). Group 3 patients, also showed 
a lower overall 24-h VAS pain score and prolonged time to first rescue 
analgesics. There was a dose dependent increase in the severity of nausea and 
vomiting with highest VAS nausea score in group 3 patients. 
 
Conclusion: 
 The combination of 50 µg or 100 µg neostigmine with 15 mg of 
hyperbaric bupivacaine, given intrathecally, delayed postoperative pain for 
4.7 – 6 h and lowered the number of rescue analgesics, in dose dependent 
manner. Because the better quality of analgesia was obtained with an 
increased (statistically significant differences) in incidence of untoward side 
effects, larger samples should be studied before this application can be 
routinely used clinically.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   ﻃﺮوﺣﺔﻣﻠﺨﺺ اﻷ
 
  :  اﻟﺪراﺳﺔ وهﺪفﺧﻠﻔﻴﺔ
آﻌﻘﺎر ﻏﻴѧﺮ أﻓﻴѧﻮﻧﻲ  ﻓѧﻲ اﻟﺘﺨѧﺪﻳﺮ  ( enimgitsoen )ﻦأﻇﻬﺮت ﻣﻌﻈﻢ اﻟﺪراﺳﺎت أن اﺳﺘﻌﻤﺎل اﻟﻨﻴﻮﺳﺘﻴﻘﻤﻴ 
  .اﻟﻨﺼﻔﻲ أدى إﻟﻰ اﻧﺨﻔﺎﺿﺎ أآﺒﺮ ﻓﻲ ﻧﺘﺎﺋﺞ اﻷﻟﻢ
 ﺮاﻟﻬﺪف ﻣﻦ هﺬﻩ اﻟﺪراﺳﺔ هﻮ ﺗﻘﻴﻴﻢ ﺗﺄﺛﻴﺮ ﺟﺮﻋﺎت ﻣﺨﺘﻠﻔﺔ ﻣѧﻦ ﻋﻘѧﺎر اﻟﻨﻴﻮﺳѧﺘﻴﻘﻤﻴﻦ ﻋﻠѧﻰ ﺧѧﺼﺎﺋﺺ اﻟﺘﺨѧﺪﻳ 
وآѧﺬﻟﻚ ﻣﻼﺣﻈѧﺔ ، (eniacavipub yvaeh) ﻣﻀﺎﻓﺔ إﻟﻰ اﻟﻤﺨﺪر اﻟﻤﻮﺿﻌﻲ ﺑﻴﻮﺑﻴﻔѧﺎآﻴﻦ اﻟﺜﻘﻴѧﻞ ،اﻟﻨﺼﻔﻲ
  .اﻟﻔﻌﺎﻟﻴﺔ واﻷﻣﺎن ﻓﻲ اﺳﺘﺨﺪاﻣﻪ  آﻤﺴﻜﻦ ﺑﻌﺪ اﻟﻌﻤﻠﻴﺎت اﻟﺠﺮاﺣﻴﺔ ﺗﺤﺖ اﻟﺴﺮة
  :ﻃﺮﻳﻘﺔ اﻟﺪراﺳﺔ 
ﻣѧѧﻦ اﻟﺪرﺟѧѧﺔ اﻷوﻟѧѧﻰ  ،ﺳѧѧﻮداﻧﻲ اﻟﺠﻨѧѧﺴﻴﺔ ( وﻣﺮﻳѧѧﻀﻪ)  ﻟѧѧﺴﺘﻮن ﻣﺮﻳѧѧﻀﺎ ﺔأﺟﺮﻳѧѧﺖ هѧѧﺬﻩ اﻟﺪراﺳѧѧﺔ اﻟﻤѧѧﺴﺘﻘﺒﻠﻴ 
 fo yteicoS naciremA)ﻟﺘѧѧѧѧѧﺼﻨﻴﻒ ﺟﻤﻌﻴѧѧѧѧѧﺔ أﺧѧѧѧѧѧﺼﺎﺋﻲ اﻟﺘﺨѧѧѧѧѧﺪﻳﺮ اﻻﻣﺮﻳﻜﻴѧѧѧѧѧﻪ واﻟﺜﺎﻧﻴѧѧѧѧѧﺔ 
 ﺣѧﻀﺮوا ﻷداء ﻋﻤﻠﻴѧﺎت ﺟﺮاﺣﻴѧﻪ  ، ﺳѧﻨﻪ 56 – 12 ﻟﻠﻴﺎﻗѧﺔ اﻟѧﺼﺤﻴﺔ ﻣѧﺎﺑﻴﻦ ﻋﻤѧﺮ  (tsigoloisehtsenA
  .ﺑﺎردة ﺗﺤﺖ ﺗﺄﺛﻴﺮ اﻟﺘﺨﺪﻳﺮ اﻟﻨﺼﻔﻲ
أﻋﻄﻴѧѧﺖ .  ﻣﺮﻳѧѧﻀﺎ02ﺗѧѧﻢ اﺧﺘﻴѧѧﺎر وﺗѧѧﺼﻨﻴﻒ اﻟﻤﺮﺿѧѧﻰ ﻋѧѧﺸﻮاﺋﻴﺎ إﻟѧѧﻰ ﺛѧѧﻼث ﻣﺠﻤﻮﻋѧѧﺎت ﻓѧѧﻲ آѧѧﻞ ﻣﻨﻬѧѧﺎ 
 ﻣﻴﻜﺮوﺟѧﺮام  ﻧﻴﻮﺳѧﺘﻴﻘﻤﻴﻦ ﻟﻠﻤﺠﻤﻮﻋѧﺔ 001  و 05وأﺿѧﻴﻒ ،  ﺑﻴﻮﺑﻴﻔﺎآﻴﻦ ﻓﻘﻂ ﻢ ﻣﻠﺠ 51ﻋﺔ اﻷوﻟﻰ اﻟﻤﺠﻤﻮ
  .اﻟﺜﺎﻧﻴﺔ واﻟﺜﺎﻟﺜﺔ ﺑﺎﻟﺘﺘﺎﻟﻲ
وﻗﺖ ﻃﻠѧﺐ اﻟﻤѧﺮﻳﺾ ﻟﻤѧﺴﻜﻦ ﺁﺧѧﺮ وﻣﻌѧﺪل اﻟѧﺸﻌﻮر ﺑѧﺎﻷﻟﻢ ، ﻣﺪة اﻟﻤﺴﻜﻦ ، ﺗﻤﺖ ﻣﻘﺎرﻧﺔ ﺑﺪاﻳﺔ ﺗﺄﺛﻴﺮ اﻟﻤﺴﻜﻦ 
ﻣﻌѧﺪل ، اﻟѧﻀﻐﻂ )ﻟﺤﻴﻮﻳѧﺔ ﻟﻠﻤﺮﺿѧﻰ آѧﺬﻟﻚ ﺗﻤѧﺖ ﻣﻘﺎرﻧѧﺔ اﻟﻌﻼﻣѧﺎت ا .   ﺳﺎﻋﺔ اﻟﺘﻲ ﺗﻠﺖ اﻟﻌﻤﻠﻴѧﺔ 42ﺧﻼل ال 
ﻟﻤѧﺪة ، ﻃѧﻮال ﻓﺘѧﺮة اﻟﻌﻤﻠﻴѧﺔ وﻓѧﻲ ﻏﺮﻓѧﺔ اﻹﻓﺎﻗѧﺔ ( وﻣﻌѧﺪل ﺗѧﺸﺒﻊ اﻟѧﺪم ﺑﺎﻷآѧﺴﺠﻴﻦ، ﺿѧﺮﺑﺎت اﻟﻘﻠѧﺐ واﻟﺘѧﻨﻔﺲ 
  . ﺳﺎﻋﺔ ﺑﻌﺪ اﻟﻌﻤﻠﻴﺔ42وﻗﺪ ﺗﻢ ﺗﺴﺠﻴﻞ أي ﺗﺄﺛﻴﺮات ﺟﺎﻧﺒﻴﺔ ﻟﻠﻌﻘﺎر ﻃﻮال ﻓﺘﺮة ال. ﺳﺎﻋﺘﻴﻦ ﺑﻌﺪ اﻟﻌﻤﻠﻴﺔ
  :اﻟﻨﺘﺎﺋﺞ 
ﻟﻤﺨѧﺪر اﻟﻤﻮﺿѧﻌﻲ ﺑﻴﻮﺑﻴﻔѧﺎآﻴﻦ ﻓѧﻲ اﻟﻤﺠﻤﻮﻋѧﺔ اﻟﺜﺎﻧﻴѧﺔ واﻟﺜﺎﻟﺜѧﺔ إﻟѧﻰ ﺗﺤѧﺴﻦ ﺑﺪاﻳѧﺔ  ﺗѧﺄﺛﻴﺮ ا أدت هﺬﻩ اﻹﺿﺎﻓﺔ 
آﺬﻟﻚ ﺗѧﻢ ﺗѧﺴﺠﻴﻞ زﻣѧﻦ أﻃѧﻮل ﻟﻘѧﺪرة اﻟﻤѧﺮﻳﺾ ﻋﻠѧﻰ ﺑﺪاﻳѧﺔ ﺗﺤﺮﻳѧﻚ اﻷﻃѧﺮاف .  ﻣﻘﺎرﻧﺔ ﺑﺎﻟﻤﺠﻤﻮﻋﺔ اﻷوﻟﻰ 
  .ورﻓﻌﻬﺎ ﻋﻦ اﻟﺴﺮﻳﺮ ﻓﻜﺎﻧﺖ أﻃﻮل ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻟﺜﺔ واﻟﺜﺎﻧﻴﺔ ﻣﻘﺎرﻧﺔ ﺑﺎﻷوﻟﻰ
آѧﺎن ﻟѧﻪ %( 5.0) اﻟﺜﻘﻴѧﻞ ﺒﻴﻮﺑﻴﻔѧﺎآﻴﻦ  ﻣѧﻊ ﻋﻘѧﺎر اﻟ ﺘﻴﻘﻤﻴﻦاﻟﻨﻴﻮﺳѧ  ﻓﻲ هﺬﻩ اﻟﺪراﺳѧﺔ وﺟѧﺪ أن  اﺳѧﺘﻌﻤﺎل ﻋﻘѧﺎر 
، آѧﺬﻟﻚ ﺗѧﻢ ﺗѧﺴﺠﻴﻞ ﻋѧﺪد اﻗѧﻞ ﻣѧﻦ اﻟﻤѧﺴﻜﻦ اﻟﺜѧﺎﻧﻮي .  ﺗѧﺄﺛﻴﺮا اﻳﺠﺎﺑﻴѧﺎ ﻓѧﻲ ﺗѧﺄﺧﻴﺮ اﻟѧﺸﻌﻮر ﺑѧﺎﻷﻟﻢ ﺑﻌѧﺪ اﻟﻌﻤﻠﻴѧﺔ 
  .اﻟﺬي ﺗﻢ اﻋﻄﺎؤة ﻟﻠﻤﺮﺿﻰ ﺑﻌﺪ اﻟﻌﻤﻠﻴﺔ ﻋﻨﺪ اﻟﺸﻌﻮر ﺑﺎﻷﻟﻢ، (canefolcid)دﻳﻜﻠﻮﻓﻴﻨﺎك 
 وﺗﻨﺎﺳﺒﺖ ﺷﺪﺗﻬﻤﺎ ﺗﻨﺎﺳﺒﺎ ﻃﺮدﻳﺎ ﻣѧﻊ زﻳѧﺎدة ،  آﺜﺮ اﻟﻤﻀﺎﻋﻔﺎت ﺣﺪوﺛﺎﻟﻘﺪ آﺎن اﻟﺸﻌﻮر ﺑﺎﻟﻐﺜﻴﺎن واﻟﻘﻲء هﻤﺎ أ 
  .اﻟﻨﻴﻮﺳﺘﻴﻘﻤﻴﻦﺟﺮﻋﺔ ﻋﻘﺎر 
  :اﻟﺨﻼﺻﺔ 
، اﻟﻨﻴﻮﺳѧﺘﻴﻘﻤﻴﻦ  ﻣѧﻦ ﻋﻘѧﺎر م ﻣﻴﻜﺮوﺟѧﺮا 001 و 05ﺧﻠﺼﺖ هﺬﻩ اﻟﺪراﺳﺔ إﻟﻰ أن اﺳﺘﻌﻤﺎل ﺟﺮﻋﺎت ﻣﺨﺘﻠﻔﺔ 
ﻧﺨﻔﺎض ﻓﻲ اﺳѧﺘﻌﻤﺎل وا(    ﺳﺎﻋﺎت 6 – 7.4)أدى إﻟﻰ ﺗﺄﺧﻴﺮ اﻟﺸﻌﻮر ﺑﺎﻷﻟﻢ ،  اﻟﺜﻘﻴﻞ ﺒﻴﻮﺑﻴﻔﺎآﻴﻦﻣﻊ ﻋﻘﺎر اﻟ 
  .ﺑﺼﻮرﻩ ﺟﻴﺪﻩ وﻣﺠﺪﻳﺔ إﺣﺼﺎﺋﻴﺎ،  اﻟﻤﺴﻜﻨﺎت ﺑﻌﺪ اﻟﻌﻤﻠﻴﺔ
ﻟѧѧﺬﻟﻚ ﻳﺠѧѧﺐ إﺟѧѧﺮاء دراﺳѧѧﺔ أﺷѧѧﻤﻞ ، ارﺗﺒﻄѧѧﺖ ﺷѧѧﺪة اﻟﺘѧѧﺄﺛﻴﺮات اﻟﺠﺎﻧﺒﻴѧѧﺔ ﺑﺰﻳѧѧﺎدة ﺟﺮﻋѧѧﺔ ﻋﻘѧѧﺎر اﻟﻨﻴﻮﺳѧѧﺘﻴﻘﻤﻴﻦ 
  . وﺑﺠﺮﻋﺎت اﻗﻞ ﻣﻦ ﺗﻠﻚ اﻟﻤﻮﺻﻰ ﺑﻬﺎ واﻟﺘﻲ اﺳﺘﺨﺪﻣﺖ ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Chapter 1 
INTRODUCTION, LITERATURE 
REVIEW AND OBJECTIVES 
 
 
 
 
 
 
 
 
 
 INTRODUCTION 
  
Acute pain is typically associated with a neuroendocrine stress response 
that is proportional to pain intensity. Moderate to sever acute postoperative 
pain, regardless of site, can affect every organ function and may adversely 
influence postoperative morbidity and mortality. The latter suggest that 
effective postoperative pain management is not only humane but also a very 
important aspect of postoperative care. (1) 
 Intrathecal and epidural administration of opioids is commonly used in 
order to provide postoperative analgesia without sensory or motor blockade. 
Unfortunately, the use of neuraxial opioids is often associated with adverse 
effects, especially delayed respiratory depression. In an attempt to develop 
non-opioid analgesics with fewer adverse effects, the activity of other 
neurotransmitters that participate in modulation of pain processing in the 
spinal cord, including acetylcholine (ACh) has been examined.(2) ( 3) 
 Recently, the spinal cholinergic system has gained new interest as a 
pharmacological target to accomplish efficient antinociception without the 
limitation of opioid-induced side effects. Thereby cholinergic agonists and 
acetylcholinesterase inhibitors were investigated with respect to their specific 
antinociceptive activity, to any potential side effects, and regard to any 
potential toxicity after their spinal administration.(4)(5) In addition, several 
interactions with different pain modulating systems like the opioid-and α2-
adrenergic receptors have been elucidated.(6) 
 It was demonstrated that ACh is present in the intrinsic spinal neurons, 
in descending supraspinal fibers as well as in primary afferent fibers. Thus, 
ACh is considered one of the major neurotransmitters in pain modulation.(7) 
Subsequently, it was shown in many studies that the spinal delivery of 
cholinergic agonists will result in analgesia, which is mediated through the 
 interaction with spinal noradrenergic-cholinergic neurons corresponding with 
neurons in lamina 1 and 2 of spinal dorsal horn. (8) 
 This analgesic action appears to be related to muscarinic receptors 
rather than nicotinic receptors activation. Thereby M1 and M2 receptors are 
suggested to be mainly involved in the spinal antinociception. However, these 
receptors will be also activated by inhibition of the breakdown of endogenous 
acetylcholinesterase. In addition, the spinal delivery of neostigmine was 
demonstrated to result in a dose-dependent analgesia in different species, 
including men. In the case of neostigmine, its analgesic potency is related to 
activation of the ACh release, and thus will be enhanced in specific pain states 
with tonic release of ACh like neuropathic pain or inflammatory pain 
disorders.(9) 
 Before its spinal use in humans, numerous animal studies in different 
species were performed, analyzing its spinal pharmacology and toxicity. After 
the assessment of its safety in the studies, intrathecal administration of 
neostigmine in healthy volunteers was performed. Thereby it was shown that 
typical non-dangerous, adverse events would be nausea, vomiting, sedation, 
slight motor weakness, increased heart rate, and blood pressure. However, all 
side effects were dependent on dose, method of administration (needle size) 
and baricity of the solution injected. (10) 
 Dose of 50 to 100 micrograms (µg) of spinally administered 
neostigmine appeared to be the optimal analgesic dose providing analgesia 
comparable to morphine, lasting 24 hours. (11) 
 Spinal administration of neostigmine as a non-opioid analgesic appears 
to provide a potent, long lasting analgesia. However, its clinical feasibility has 
still to be assessed with special regards to its side effects, mainly nausea and 
vomiting. Promising perspectives of spinally administered neostigmine will 
be its use as an analgesic in distinct pain states such as Neuropathic or cancer 
related pain syndrome.  
 LITERATURE REVIEW  
1. SPINAL ANAESTHESIA 
1.1   INTRODUCTION: 
Spinal, caudal and epidural blocks (neuraxial anaesthesia) were first 
used for surgical procedures at the turn of last century when August Biers 
credited with administering the first spinal anaesthesia in 1898; he used 3ml 
of 0.5 cocaine intrathecally. (12)  
 These central blocks were widely used prior to the 1940s until 
increasing reports of permanent neurologic injury appeared. (13)  
 Publication of a large–scale epidemiological study in the 1950s showed 
that complications were rare when these blocks were performed skillfully 
with attention to asepsis and newer, safer local anaesthetics were used. (14) (15)   
Sir Robert Macintosh was a giant of our specialty (1897-1989). As an author, 
his books (particularly Local Anesthesia: Brachial Plexus, and Lumbar 
Puncture and Spinal Anesthesia) were very influential. Resurgence in the 
used of central blocks ensued, and today, they are once again widely used in 
clinical practice. (16) 
 Spinal anaesthesia is easy to perform and has the potential to provide 
excellent operating conditions for surgery below umbilicus. If the anaesthetist 
has an adequate knowledge of the relevant anatomy, physiology, and 
pharmacology, safe and satisfactory anaesthesia can easily be obtained to the 
mutual satisfaction    of the patient, surgeon and anaesthetist. 
 Spinal anaesthesia is induced by injecting a small amount of local 
anaesthetic (LA) into the cerebro-spinal fluid (CSF). The injection is usually 
made in the lumbar spine below the level at which spinal cord ends (L2). 
 1.2    ADVANTAGES OF SPINAL ANAESTHESIA: 
? Cost: Anaesthetic drugs and gases are costly and the latter often 
difficult to transport. The costs associated with spinal anaesthesia are 
minimal. (17) 
? Patient satisfaction: If a spinal anaesthetic and the ensuing surgery are 
performed skilfully, the majority of patients is very happy with the technique 
and appreciates the rapid recovery and absence of side effects. 
? Respiratory disease: Spinal anaesthesia produces few adverse effects 
on the respiratory system as long as unduly high blocks are avoided. 
Reduction of parental opiate requirements may decrease the incidence of 
aspiration pneumonia and hypoventilation. (18) 
? Patent airway: As control of the airway is not compromised, there is a 
reduced risk of airway obstruction or the aspiration of gastric contents. This 
advantage may be lost if too much sedation is given. 
? Diabetic patients: There is little risk of unrecognized hypoglycaemia 
in an awake patient. Diabetic patients can usually return to their normal food 
and insulin regime soon after surgery as they experience less sedation, nausea 
and vomiting. (19) 
? Muscle relaxation: Spinal anaesthesia provides excellent muscle 
relaxation for lower abdominal and lower limb surgery. 
? Bleeding: Blood loss during operation is less than when the same 
operation is done under general anaesthesia. This is because of a fall in blood 
pressure and heart rate and improved venous drainage with a resultant 
decrease in oozing. 
? Splanchnic blood flow: Because it increases blood flow to the gut, 
spinal anaesthesia may reduce the incidence of anastomotic dehiscence. 
? Visceral tone: The bowel is contracted during spinal anaesthesia and 
sphincters are relaxed although peristalsis continues. Normal gut function 
rapidly returns following surgery. 
 ? Coagulation: Post-operative deep vein thromboses and pulmonary 
emboli are less common following spinal anaesthesia. (20) 
? Cardiac disease: SA may reduce the incidence of cardiac 
complications in high risk patients. Decreasing the neuroendocrine stress 
response to surgery, patients with coronary artery disease may show less 
perioperative ischemia and reduce morbidity and mortality. 
? Cesarean section: It is most commonly performed under spinal or 
epidural anaesthesia. It allows a mother to remain a wake and experience the 
birth of here child. Large population studies in Great Britain and in the USA 
have shown that regional anaesthesia is associated with less maternal 
morbidity and mortality than is GA, which may be largely due to reducing the 
incidence of pulmonary aspiration and failed intubation. (21) 
1.3   DISADVANTAGES OF SPINAL ANAESTHESIA: 
SA techniques have proved to be extremely safe when managed well; 
however, there is still a risk for complications. Adverse reactions and 
complications range from self-limited back soreness to debilitating permanent 
neurologic deficits and even death.  
  The practitioner must therefore have a good understanding of the 
anatomy involved, be thoroughly familiar with the pharmacology and toxic 
dosages of the agents employed, diligently employ sterile technique and 
quickly treat physiologic derangement. 
 Some patients are not psychologically suited to be awake, even if 
sedated, during an operation. They should be identified during the 
preoperative assessment. Likewise, some surgeons find it very stressful to 
operate on conscious patients. 
 Even if a long-acting local anaesthetic is used, a spinal anaesthesia is 
not suitable for surgery lasting longer than approximately 2 hours. Patients 
find lying on an operating table for long periods uncomfortable. If an 
operation unexpectedly lasts longer than this, it may be necessary to convert 
 to a general anaesthetic or supplement the anaesthetic with intravenous 
ketamine or with a propofol infusion if that drug is available. 
1.4   ANATOMY OF SPINAL CORD 
1.4.1 The vertebral column: 
The spinal cord (SC) and its nerve roots lie within the central bony 
canal of the vertebral column (VC) which is made up of 7 cervical, 12 
thoracic, 5 lumbar, 5 sacral, and 4 coccygeal. With some notable exceptions, 
most vertebrae have similar features: a vertebral body anteriorly, two pedicles 
laterally, and two laminae posterioly. Each has a midline spinous process that 
arises between the laminae and two transverse processes that arise laterally at 
the junction of the lamina and pedicle. These processes serve as attachments 
for ligaments and muscles. (22) 
 The first cervical vertebra, the atlas, lacks a body and has unique 
articulations with the base of the skull and the second vertebra. The later, also 
called the axis, consequently has atypical articulating surfaces. Sacral 
vertebrae normally fuse into one large bone, the sacrum. The lamina of S5 and 
all or parts of S4 normally don't fuse, leaving a caudal opening to the spinal 
canal, the sacral hiatus. Coccygeal vertebrae are small rudimentary structures 
that also fuse. 
 Ligamentous elements provide structural support and together with 
supporting muscles help to maintain the unique double C-shape of the SC. 
Ventrally, the vertebral bodies and intervertebral disks are connected and 
supported by the anterior and posterior longitudinal ligaments. Dorsally, the 
ligamentum flavum, interspinous, and supraspinous ligament provide 
additional stability. 
1.4.2 The spinal cord: 
The spinal canal contains the SC with its coverings (meninges), fatty 
tissue, and a venous plexus. The meninges are composed of three layers: the 
 pia mater, arachnoid and the durra mater. The pia mater is closely adherent to 
the SC. CSF is contained between the pia and arachnoid maters in the 
subarachnoid space. The spinal subdural space is generally a poorly 
demarcated, potential space. The epidural space is a better defined potential 
space within the SC that is bounded by the dura and the ligamentum flavum.  
  The SC normally extends to the level of L1 in adults and L3 in children 
but moves up as they grow older. The anterior and posterior nerve roots at 
each spinal level join one another and exit the intervertebral foramina forming 
spinal nerves from C1 to S4.  
 Because the SC normally ends at L1, lower nerve roots must travel an 
increasing distance (within the lumbar and sacral subarachnoid and epidural 
spaces) from the SC to the intervertebral foramina. These lower spinal nerves 
form the cauda equine, which is floating in the dural sac below L1 and tend 
to be pushed away (rather than pierced) by an advancing needle. 
 A dural sheath invests most nerve roots for a small distance even after 
they exit the SC.  
 The blood supply to SC and nerve roots is derived from a single 
anterior spinal artery and paired posterior spinal arteries. The anterior 
spinal artery is formed from the vertebral artery at the base of the skull. It 
supplies the anterior two-thirds of the cord, whereas the two posterior spinal 
arteries supply the posterior one-third. They arise from the inferior cerebellar 
arteries. The anterior and posterior spinal arteries receive additional blood 
flow from the intercostal arteries in the thorax and the lumbar arteries in the 
abdomen. One of these radicular arteries is typically large, the artery of 
Adamkiewicz, arising from the aorta. 
1.4.3 Surface anatomy: 
Spinous processes are generally palpable and help to define the midline of 
the back. (23) Some useful surface markings: 
 ? The Spinous processes of the cervical and lumbar spines are nearly 
horizontal whereas those in the thoracic spine slant in a caudal direction and 
can overlap significantly. 
? The vertebral prominence (spine of C7) is easily palpable. 
? The tip of the spine T3 is opposite the roots of the spines scapula, with 
arms at the sides of the body. 
? The tip of the spine T7 is opposite the inferior angle of the scapula, with 
arms to the sides.  
? The highest points of the iliac crests are usually on a line crossing the 
spine of L4 or the L4-L5 interspace. 
? The dimples overlying the posterior superior iliac spines are on a line 
crossing the second, posterior sacral foramina and at this level the dural sac in 
the adult usually ends. 
? The lower end of the SC terminates at the level of the upper border of 
the body of L2. 
1.5   PHYSIOLOGY OF SPINAL CORD 
The principal site of action of neuraxial blockade is the nerve root. 
Local anaesthetic (LA) is injected into CSF and baths the nerve root in the 
subarachnoid space. The CSF concentration of LA is thought to have minimal 
effects on the SC itself. Direct injection of LA into CSF, however, allows a 
relatively small quantity and volume of LA to a chief high level of sensory 
and motor blockade. Blockade of neural transmission in the posterior nerve 
root fibers interrupts somatic and visceral sensation while blockade of anterior 
nerve root fibers prevents efferent motor and autonomic outflow. (24) 
1.5.1 Somatic blockade:  
By interrupting the transmission of painful stimuli (both somatic and 
visceral) and abolishing skeletal muscle tone, spinal blocks can provide 
excellent operating conditions. The effect of LA on nerve fibers varies 
according to the size of the nerve fiber, whether or not it is myelinated, and 
 the concentration achieved and the duration of contact. Smaller and 
myelinated fibers are generally more easily blocked than larger unmyelinated 
ones. Table 1 contains the most commonly used classification systems for 
nerve fibers. (25)  
 In general, the concentration of LA decreases with increasing distance 
from the level of injection as does the concentration gradients. Differential 
blockade typically results in sympathetic blockade that may be two segments 
higher than the sensory block, which in turn is two segments higher than 
motor blockade. (26)  
 
Table 1: classification of peripheral nerves according to fiber size and 
physiologic properties: 
  
 
Fiber
Class
Sub-
class
Myelin Diameter
(µ)
Conduction
Velocity 
(m/s)
Location function
α + 6-22 30-120 Afferent to and 
efferent from 
muscles and 
joints
Motor, 
proprioception
β + 6-22 30-120 Afferent to and 
efferent from 
muscles and 
joints
Motor, 
proprioception
γ + 3-6 15-35 Efferent to 
muscle 
spindles
Muscle tone
A
δ + 1-4 5-25 Afferent 
sensory nerve
Pain, 
temperature, 
touch
B + <3 3-15 Preganglionic 
sympathetic
Various 
autonomic 
functions
- 0.3-1.3 0.7-1.3 Postganglionic 
sympathetic
Various 
autonomic 
functions
C
- Afferent 
sensory nerves
Pain, 
temperature, 
touch
 1.5.2 Autonomic blockade: 
Interruption of efferent autonomic transmission at the spinal nerve roots 
can produce sympathetic and some parasympathetic blockade. Sympathetic 
outflow from SC may be described as thoracolumbar, while parasympathetic 
outflow is craniosacral. Neuraxial blocks therefore primarily result in varying 
degrees of sympathetic blockade and physiologic responses, resulting from 
decreased sympathetic tone and/or unopposed parasympathetic tone. 
? Cardiovascular manifestations: 
Spinal anaesthesia typically produces variable decrease in BP that may 
be accompanied by a decrease in heart rate and cardiac contractility. These 
effects are generally proportional to the degree (level) of the sympathectomy. 
Vasomotor tone is primarily determined by sympathetic fibers arising from T5 
to L1, innervating arterial and venous smooth muscle. Blocking these nerves 
causes vasodilatation of the venous capacitance vessels, pooling of blood, and 
decreased preload to the heart; in some instances, arterial vasodilatation may 
also decrease SVR. The effects of arterial vasodilatation may be minimized 
by compensatory vasoconstriction above the level of the blockade. A high 
sympathetic block not only prevents compensatory vasoconstriction but also 
blocks the sympathetic cardiac accelerator fibers that arise at T1-T4. 
 Profound hypotension may result from vasodilatation combined with 
bradycardia and decreased contractility. These effects are exaggerated if 
venous return is further compromised by a head-up position or from the 
weight of a gravid uterus. Unopposed vagal tone in some persons may explain 
cardiac arrest with SA. (27) 
 Deleterious cardiovascular effects should be anticipated and steps 
undertaken to minimize the degree of hypotension. 
? Pulmonary manifestations: 
SA to mid-thorax levels have little effect on pulmonary function in 
patients without pre-existing disease (drugs for sedation may have a greater 
effect). 
  The adverse impact of high blocks on active exhalation suggests 
caution when using SA in patients with COPD or those who rely on accessory 
muscles of respiration to maintain adequate ventilation. 
 Patients with high spinal may complain of dyspnea (loss of ability to 
feel chest movement while breathing, which is usually adequately treated by 
reassurance). A normal speaking voice, suggests ventilation is normal (faint 
gasping whisper with an excessively high block). 
? Gastrointestinal manifestations: 
Sympathetic outflow originates at the T5 - L1 level. SA induced 
sympathectomy allows vagal tone dominance and results in a small, 
contracted gut with active peristalsis that can provide excellent operative 
conditions. 
 Nausea is a common complication of SA (cause is unknown but often 
associated with; (1)blocks higher than T5; (2)hypotension; (3)opioid 
administration; (4)traction on nerve endings and plexuses, especially via 
vagus; (5)psychological factors; (6)hypoxia; (7)presence of bile in stomach 
due to relaxation of pyloric and bile-duct sphincters). (28) Treatment of nausea 
and vomiting consists in attending to the hypotension and hypoxia, if present; 
i.v. atropine; oxygen supplementation; deep breathing through the mouth; 
reassurance and attention to general comfort; antiemetics supplementation; 
i.v. anaesthesia with thiopentone and nitrous oxide-oxygen, or a volatile 
agent, if the condition persists or if the surgeon's work is being affected- full 
general anaesthesia. (29)  
? Hepatic manifestations: 
There are no specific effects of significance. Hepatic blood flow will 
decrease with reductions in mean arterial pressure from any anaesthetic 
technique. For intra-abdominal surgery the decrease in hepatic perfusion is 
more related to surgical manipulation than anaesthetic technique. Liver 
disease may interfere with the metabolism of LA drugs. 
 ? Urinary tract manifestations: 
Renal blood flow is maintained through autoregulation, and there is 
little clinical effect upon renal function from SA. (30)  
 SA at the lumbar and sacral levels blocks both sympathetic and 
parasympathetic control of bladder function. Loss of autonomic bladder 
control results in urinary retention. If no urinary catheter is anticipated 
perioperatively, it is prudent to use shortest acting and least a moment of drug 
necessary for the surgical procedure and limit the amount of i.v. fluid 
administration (if possible). 
? Metabolic and endocrine manifestations: 
Spinal blockade can partially suppress (during major invasive surgery) 
or a totally block (during lower extremity surgery) the neuroendocrine 
response which stimulated by the surgical trauma. A T11 block can block 
adrenal pathways and blunt hyperglycemia. By reducing catecholamine 
release, SA may decrease perioperative arrhythmias and possibly reduce the 
incidence of ischemia. 
1.6   INDICATIONS FOR SPINAL ANAESTHESIA: 
These vary greatly with different surgeons and anaesthetists. SA is best 
reserved for operations below the umbilicus e.g. hernia repairs, gynecological 
and urological operations and any operation on the perineum or genitalia. All 
operations on the leg are possible, but an amputation, though painless, may be 
unpleasant experience for an awake patient. In this situation it may be 
appropriate to combine the spinal with a light GA. 
 SA is particularly suitable for older patients and those with systemic 
diseases such as respiratory disease, hepatic, renal, and endocrine such as 
diabetes. (31)  
Useful when muscle relaxants are contra-indicated, or when it is 
thought advantageous to preserve spontaneous respiration. Patients with 
 chronic respiratory disease often do well with central neural blockade as 
tracheal intubation may be avoided.  
Some patients fear loss of consciousness and prefer to remain awake. 
Acute cases, including obstetric patients, with a full stomach are of less risk 
of inhalation of stomach contents under spinal than with GA.(32) There are 
definite advantages for both mother and baby in using spinal anaesthesia for 
caesarean section. However, special considerations apply to managing spinal 
anaesthesia in pregnant patients and it is best to become experienced in its use 
in the non-pregnant patient before using it for obstetrics.  Some patients with 
compromised hepatorenal function may do well with central neural 
blockade. Skilled workers may meet fewer difficulties with SA than with GA 
in the morbidly obese patient. It is suitable for managing patients with 
trauma if they have been adequately resuscitated and are not hypovolaemic. 
(33) 
 1.7   CONTRAINDICATIONS FOR SPINAL ANAESTHESIA: 
Most of the contra-indications to spinal anaesthesia apply equally to 
other forms of regional anaesthesia. These include: 
? Inadequate resuscitation drugs and equipment: No regional 
anaesthetic technique should be attempted if drugs and equipment for 
resuscitation are not immediately to hand. 
? Clotting disorders: If bleeding occurs into the epidural space because 
the spinal needle has punctured an epidural vein, a haematoma could form 
and compress the spinal cord. Patients with a low platelet count or receiving 
anticoagulant drugs such as heparin or warfarin are at risk. Remember that 
patients with liver disease may have abnormal clotting profiles whilst low 
platelet counts as well as abnormal clotting can occur in pre-eclampsia. 
? Hypovolaemia: If patients are hypovolaemic from whatever cause e.g. 
bleeding, dehydration due to vomiting, diarrhoea or bowel obstruction, 
 patients must be adequately rehydrated or resuscitated before spinal 
anaesthesia or they will become very hypotensive. 
? Patient refusal: Patients may be understandably apprehensive and 
initially state a preference for general anaesthesia, but if the advantages of 
spinal anaesthesia are explained they may then agree to the procedure and be 
pleasantly surprised at the outcome. If, despite adequate explanation, the 
patient still refuses spinal anaesthesia, their wishes should be respected. 
Likewise, mentally handicapped patients and those with psychiatric problems 
need careful pre-operative assessment. 
? Children: Although spinal anaesthesia has been successfully 
performed on children, this is a highly specialised technique best left to 
experienced paediatric anaesthetists. (34) 
? Sepsis: Infection on the back near the site of lumbar puncture let 
infection be introduced into the epidural or intrathecal space. 
? Septicemia: If a patient is septicemic, they are at increased risk of 
developing a spinal abscess. Epidural abscesses can, however, appear 
spontaneously in patients who have not had spinal/epidural injections 
especially if they are immuno-deficient: e.g. patients with AIDS, tuberculosis, 
and diabetes. 
? An anatomical deformity of the patient's back: This is a relative 
contraindication, as it will probably only serve to make the dural puncture 
more difficult. 
? Neurological disease: The advantages and disadvantages of spinal 
anaesthesia in the presence of neurological disease need careful assessment. 
Any worsening of the disease post-operatively may be blamed erroneously on 
the spinal anaesthetic. Raised intracranial pressure, however, is an absolute 
contra-indication as a dural puncture may precipitate coning of the brain 
stem.  
Absolute, Relative and controversial contraindications are also listed in 
table 2. 
 Table 2: contraindications to neuraxial blockade: 
 
? Absolute 
? Infection at the site of injection 
? Patient refusal 
? Coagulopathy or other bleeding diathesis 
? Sever Hypovolaemia 
? Increased intracranial pressure 
? Sever aortic stenosis 
? Sever mitral stenosis 
? Relative 
? Sepsis 
? Uncooperative patient 
? Preexisting neurological deficit 
? Stenotic valvular heart disease 
? Sever spinal deformity 
? controversial  
? prior back surgery at the site of injection 
? inability to communicate with patient 
? complicated surgery 
? Prolonged operation 
? Major blood loss 
? Maneuvers that compromise respiration. 
 
 
    
1.8   FACTORS INFLUENCING LEVEL OF BLOCK: 
A number of factors affect the spread of the injected local anaesthetic 
solution within the CSF and the ultimate extent of the block obtained. 
 Among these are: 
 ? the baricity of the local anaesthetic solution, 
? the position of the patient, 
? the concentration and volume injected,  
? the level of injection,  
? the speed of injection, and 
? Other factors: age, CSF, curvature of the spine, intra-abdominal 
pressure, needle direction, patient height, and pregnancy. 
 
Migration of local anaesthetic cephalad in CSF depends on its specific 
gravity relative to CSF (baricity). CSF has a specific gravity of 1.003-1.008. 
The specific gravity of the local anaesthetic solution can be altered by the 
addition of dextrose. Concentrations of 7.5% dextrose make the local 
anaesthetic hyperbaric (heavy) relative to CSF and also reduce the rate at 
which it diffuses and mixes with the CSF.(35) Isobaric and hyperbaric 
solutions both produce reliable blocks. Injecting hyperbaric solutions and then 
altering the patient's position probably produces the most controllable blocks. 
If a patient is kept sitting for several minutes after the injection of a 
small volume of a hyperbaric solution of local anaesthetic, a classical "saddle 
block" affecting only the sacral nerve roots will result. (36) 
The quantity of local anaesthetic (in milligrams) injected will determine 
the quality of the block obtained whilst its extent will also be determined by 
the volume in which it is injected. Large volumes of concentrated solutions 
will, thus, produce dense blockade over a large area. As spinal anaesthetics 
are generally only injected in the lumbar region, the extent of the block is 
influenced more by the volume and concentration injected and the position of 
the patient than the actual interspace at which the injection occurs. 
The speed of injection has a slight effect on the eventual extent of the 
block. Slow injections result in a more predictable spread while rapid 
injections produce eddy currents within the CSF and a somewhat less 
predictable outcome. (37) 
 Finally, increased abdominal pressure from whatever cause (pregnancy, 
ascites etc.) can lead to engorgement of the epidural veins, compression of the 
dura and hence a reduction in the volume of the CSF. A given quantity of 
local anaesthetic injected into the CSF might then be expected to produce a 
more extensive block. (38) 
1.9   SPINAL ANAESTHETIC AGENTS: 
Many local anaesthetics have been used for SA in the past, but only a 
few currently in uses (procaine 10%, bupivacaine 0.5-0.7.5%, tetracaine1%, 
lidocaine 5%, and robivacaine 0.2-1%). Only preservative-free local 
anaesthetics are used. (39) 
 Addition of vasoconstrictors (40) (α- adrenergic agonists) and opioids (41) 
greatly enhances the quality of SA vasoconstrictors include epinephrine (0.1-
0.2mg) and phenylephrine (1-2mg). Both agents appear to decrease the uptake 
and clearance of local anaesthetics from CSF and may have weak analgesic 
properties. (42) 
 Clonidine (α2-adrenergic agonist) provides dose-dependent analgesia 
and side effects of hypotension, bradycardia, and sedation, but not respiratory 
depression or pruritus. (43) (44) (45) Acetylcholinesterase (e.g. neostigmine) also 
has spinal analgesic properties. (46)  
 
1.10    COMPLICATIONS OF SPINAL ANAESTHESIA: 
 
The complications of SA range from the bother some to the crippling 
and life-threatening. Broadly, the complications can be thought of as those 
resulting from the medication introduced or the needle used. Backache, 
headache, nerve injury, vascular injury, and infection can result from the 
procedure needle. Medications can result in excessively high blockade, 
systemic toxicity, local toxicity (nerve injury) or infection. Ischemic injury 
may result from combination of factors. Cardiac arrest can occur with SA. (47) 
 
 ? Backache: 
It usually benign and self-limited, although it may last for a number of 
weeks, it may also be an important clinical sign of the much more serious 
complications, such as epidural haematoma and abscess. A localized 
inflammatory response with or without reflex muscle spasm may be 
responsible. 
? Headache: 
 The first successful spinal anaesthetic by August Bier (1898) was 
accompanied by a classic description of post-dural puncture headache 
(PDPH). Any breach of the dura may result in a PDPH. Typically the 
headache is bilateral, frontal or retro-orbital, occipital and extending into the 
neck. It may be throbbing or constant and associated with photophobia and 
nausea. The hallmark of PDPH is its association with body position, 
aggravated by sitting or standing and relieved or lessened by lying down 
flat. The onset is usually 12-72 hours following the procedure; however, it 
may be seen sooner. Untreated, the pain may last weeks, and in rare instances 
has required surgical repair. (48)  
 PDPH is believed to result from decreased intracranial pressure as CSF 
leaks from the dural defect at a greater rate than it is being produced. Recent 
data support this empiric mechanism of CSF loss causing PDPH, as MRI 
correlates CSF loss with PDPH. (49) The incidence is related to needle size, 
needle type and patient population. The greater the needle is the greeter the 
incidence of PDPH.(50) Cutting point needles are associated a higher incidence 
of PDPH than pencil point needles of the same gauge. Factors that increase 
the risk of PDPH include young age, female sex, and pregnancy. 
 Current non-invasive treatments (recumbent positioning, bed rest, 
fluids, analgesics, caffeine) only temporize the discomfort. (51) Epidural blood 
patch is a very effective treatment for PDPH. It involves injecting 15-20 ml of 
autologous blood into the epidural space at or one interspace below the level 
of the dural puncture. It is believed to stop further leakage of CSF by either 
 mass effect or coagulation. Approximately 90% of patients will respond to a 
single blood patch, and 90% of initial non-responders will get relief from a 
second injection. Epidural patching with non blood substances (e.g. saline or 
colloid) are ineffective for prolonged relieve. (52) Clinical strategies have 
focused on prophylactically reducing loss after dural puncture. 
? Urinary retention: 
 As the sacral autonomic fibers are among the last to recover following 
a spinal anaesthetic, urinary retention may occur. If fluid pre-loading has been 
excessive, a painful distended bladder may result and the patient may need to 
be catheterized. 
? Transient neurological symptoms: 
 First described in 1993, transient neurological symptoms (TNS) is 
characterized by back pain radiating to the legs without sensory or motor 
deficit, occurring after the resolution of  spinal  block and resolving 
spontaneously within several days. (53) It is most commonly associated with 
hyperbaric lidocaine, but also been reported with others. It is highest among 
outpatients (early ambulation) after surgery in the lithotomy position. (54) 
 The pathogenesis of TNS is unclear and controversy exist as to 
whether it represents neurotoxicity (a mild form of the cauda equina 
syndrome), or myofacial pain resulting from musculoskeletal strain. 
? Cardiac arrest during spinal anaesthesia: 
Examination of data from the American Society of anesthesiologist 
Close Claim project identified several cases of cardiac arrest during SA. (55) A 
analysis indicate that the administration of sedation to produce a sleep-like 
state, with unrecognized hypoventilation (hypoxia) and lack of early 
administration of epinephrine were common patterns of management in cases 
of cardiac arrest. 
Large surveillance studies typically observed incidences of 
hypotension around (33%) and bradycardia around (13%). (56) Prophylactic 
 volume expansion is recommended, as is early vagolytic (atropine) treatment 
of bradycardia followed by ephedrine and epinephrine if necessary. 
? Permanent neurological complications: 
They are extremely rare. Many of those that have been reported were 
due to the injection of inappropriate drugs or chemicals into the CSF 
producing meningitis, arachnoiditis, transverse myelitis or the cauda 
equina syndrome with varying patterns of neurological impairment and 
sphincter disturbances. (57) (58) Damage to an epidural vein can lead to the 
formation of an epidural haematoma that compresses the spinal cord. This 
is most unlikely in a patient with a normal clotting profile. If inadequate 
sterile precautions are taken, bacterial meningitis or an epidural abscess 
may result although it is thought that most such abscesses are caused by 
the spread of infection in the blood. (59) (60) Finally, permanent paralysis can 
occur due to the "anterior spinal artery syndrome". This is most likely to 
affect elderly patients who are subjected to prolonged periods of 
hypotension and may result in permanent paralysis of the lower limbs. 
? Spinal or epidural haematoma: 
The incidence of such haematomas has been estimated to be about 
1:150,000 for epidural blocks and 1:220,000 for spinal anaesthetics. The 
onset of symptoms is typically more sudden onset compared with epidural 
abscess. Symptoms include sharp back and leg pain with a progression to 
numbness and motor weakness and/or sphincter dysfunction. Diagnosis 
and surgical decompression within 8-12 hrs of the onset of symptoms 
results in a good outcome. (61) 
 Spinal haematoma carries with it a rare but well-recognized risk of cord 
damage and paralysis or permanent anaesthesia.  Abnormal clotting 
profiles either secondary to disease or pharmacologic therapies, hepatic 
cirrhosis, chronic renal failure, and spinabifida occulta, were reported risk 
factors. (62) (63) (64) 
 Cranial subdural haematomas have occurred after lumbar puncture (L.P) 
in association with cerebral aneurysm, brain tumour, recent accident and 
meningovascular syphilis. It is postulated that the haemorrhage is caused 
by a sudden decrease in intra cranial pressure consequent to the loss CSF 
at the L.P site. Sudden caudal shift of the brain may cause traction on the 
arachnoid matter and/or venous structures and may lead to bleeding from 
ruptured vessels. (65) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2.   SPINAL CORD PHYSIOLOGY AND 
PHARMACOLOGY OF PAIN 
 
 Normal pain perception depends on specialized neurons that function as 
receptors, detecting the stimulus, and then transduction, and conducting it into 
the CNS. Sensation is often described as either protopathic (noxious) or 
epicritic (non-noxious). Non-noxious sensation (light touch, pressure, 
proprioception, and temperature discrimination) is characterized by low-
threshold receptors and generally conducted by large myelinated nerve fibers. 
In contrast, noxious sensation (pain) is subserved by high-threshold receptors 
and conducted by smaller, lightly myelinated (Aδ) and unmyelinated (C) 
fibers.  
2.1   DEFINITION AND CLASSIFICATION OF PAIN: 
Pain is defined as" an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of 
such damage." 
 The term nociception is used only to describe the neural response to 
traumatic or noxious stimuli. 
 Pain is classified according to pathophysiology, (e.g. nociceptive or 
neuropathic pain), etiology (e.g. postoperative or cancer pain), or the affected 
area (e.g. headache or low back pain). However, it is clinically useful to 
divide pain into one of two categories: (1) acute pain, which may be primarily 
due to nociception, and (2) chronic pain, which may be due to nociception but 
in which psychological and behavioral factors often play a major role. 
Nociceptive pain is due to activation or sensitization of peripheral 
nociceptors, specialized receptors that transduce noxious stimuli. 
Neuropathic pain is the result of injury or acquired abnormality of peripheral 
or central structures. 
 Acute pain can be defined as that which is caused by noxious 
stimulation due to injury, a disease process, or an abnormal function of 
muscle or viscera. Four physiological processes are involved: transduction, 
transmission, modulation, and perception. This type of pain is typically 
associated with a neuroendocrine stress that is proportional to intensity. Two 
types of acute (nociceptive) pain;  
Somatic and visceral are differentiated based on origin and feature: (1) 
somatic pain, which can be further classified as superficial or deep, (2) 
visceral pain, this form of acute pain is due to a disease process or abnormal 
function of an internal organ or its covering. 
2.2 ANATOMY OF NOCICEPTION 
 
2.2.1 Pain pathways: 
 Pain is conducted along neuron pathways that transmit noxious stimuli 
from the periphery to the cerebral cortex. Primary afferent neurons are 
located in dorsal root ganglia, which lie in the vertebral foramina at each SC 
level. Each neuron has a single axon that bifurcates, sending one end to the 
peripheral tissues it innervates and the other into the dorsal horn of the SC. In 
the dorsal horn, the primary afferent neuron synapses with a second-order 
neurons whose axon cross the midline and ascend in the contralateral 
spinothalamic tract to reach the thalamus. Second order neurons synapse in 
thalamic nuclei with third order neurons, which in turn send projections 
through the internal capsule and corona radiate to the postcentral gyrus of the 
cerebral cortex. 
? First-order neurons; the majority of first-order neurons send the 
proximal end of their axons into the SC via dorsal (sensory) spinal root at 
each level. Once in the dorsal horn, in addition to synapsing with second-
order neurons, the axons of first-order neurons may synapse with 
interneurons, sympathetic neurons and ventral horn motor neurons. 
 ? Second-order neurons; pain fibers may ascend or descend one to three 
SC segments in Lissaure's tract before synapsing with second-order neurons 
in the gray matter  of the ipsilateral dorsal horn. In many instances they 
communicate with second-order neurons through interneurons. 
SC gray matter was divided by Rexed into 10 laminae. The first 6 
laminae, which make up the dorsal horn, receive all afferent neuronal activity, 
and represent the principal site of modulation of pain by ascending and 
descending neural pathways. Second-order neurons are either nociceptive-
specific or wide dynamic range (WDR) neurons.  
Nociceptive-specific neurons serve only noxious stimuli, but WDR 
neurons also receive non-noxious afferent input for Aβ, Aδ, and C fibers. 
Nociceptive specific neurons   are arranged somatotopically in lamina 1 and 
have discrete, somatic receptive fields and respond only to high threshold 
noxious stimulation. WDR neurons are the most prevalent cell type in the 
dorsal horn. Although they are found throughout the dorsal horn, WDR 
neurons are most abundant in lamina 5. During repeated stimulation, WDR 
neurons characteristically increase their firing rate exponentially in a graded 
fashion (" wind-up") even with the same stimulus intensity. 
Most nociceptive C fibers send collateral to, or terminate on, second-
order neurons in lamina 1, 2, and to a lesser extent lamina 5. In contrast, 
nociceptive Aδ fibers synapse mainly in lamina 1, 5 and to a lesser degree 
lamina 10. Lamina 1 responds primarily to noxious (nociceptive) stimulation 
from cutaneous and deep somatic tissues. 
Lamina2, also called the substantia gelatinosa, contains many 
interneurons and is believed to play a major role in processing and 
modulating nociceptive input from cutaneous nociceptors. It is also of special 
interest because it is believed to be a major site of action for opioids. Lamina 
8 and 9 make up the anterior (motor) horn. Lamina7 is called the 
intermediolateral column and contains the cell bodies of preganglionic 
sympathetic neurons. 
 Visceral afferent terminate primarily in lamina 5, and to a lesser extent 
lamina1. Lamina 5 responds to both noxious and non-noxious sensory input 
and receives both visceral and somatic pain afferent.  
The axons of most second-order neurons cross the mid-line close their 
level of origin (at the anterior commissure) to the contralateral of the SC 
before they form the spinothalamic tract and send their fibers to the thalamus, 
the reticular formation, the nucleus raphe magnus, and the periaqueductal 
gyrus. Other ascending pain pathways are also important e.g. spinoreticular, 
spinomesencephalic, spinohypothalamic, and spinotelencephalic tracts. 
Somatic and visceral afferents are fully integrated with skeletal motor 
and sympathetic symptoms in the SC, brain stem, and higher centers. 
2.3   PHYSIOLOGY OF PAIN (NOCICEPTION): 
2.3.1 Central modulation of pain; 
 Modulation of pain occurs peripherally at the nociceptors, in the SC, or 
in the supraspinal structure. The central modulation can either inhibit 
(suppress) or facilitate (aggravate) pain. 
?  Facilitation: neurochemical mediators of central sensitization include 
substance P (sP), VIP, calcitonin gene-related peptide (CGRP), 
cholecystokinin (CCK), angiotensin, and galanin as well as the excitatory 
amino acids (AAs) L-glutamate and L-asparate (sP and CGRP are the most 
important of these peptides, while glutamate is the most important excitatory 
AA ). These substances trigger changes in membrane excitability by 
interacting with G protein-coupled membrane receptors on neurons activating 
intracellular second messengers. A common pathway is an increase in 
intracellular calcium. The AAs are believed to be largely responsible for the 
induction and maintenance of central sensitization. (66) 
? Inhibition:  transmission of nociceptive input in the SC can be 
inhibited by segmental activity in the cord it-self, as well as descending neural 
activity from supraspinal centers.  
 The inhibitory neurotransmitters (somatostatin, ACh, enkephaline, β-
endorphin, norepinephrine, GABA, and glycine) produce a hyperpolarization 
of the postsynaptic membrane called the inhibitory postsynaptic potential. 
They modulate nociceptive activity in the dorsal horn. Glycine and GABA 
are the most common inhibitory neurotransmitters within the CNS. They 
likely play an important role in segmental inhibition of pain in the SC. (67) 
? Supraspinal inhibition: several Supraspinal structures and fibers 
(descending pathways) down the SC to inhibit pain in the dorsal horn. Axons 
from these tracts act presynaptically on primary afferent neurons and 
postsynaptically on second-order neurons (or interneurons). These pathways 
mediate their antinociceptive action via α2-adrenergic, sertonergic and opiate 
(µ, δ, and κ) receptor mechanism (the antidepressants-monoamines, block 
reuptake of catecholamine and serotonin). The endogenous opiate system act 
presynaptically to hyperpolarize primary afferent neurons and inhibit the 
release of sP. In contrast, exogenous opioids may preferentially act 
postsynaptically on the second-order neurons or interneurons in the substantia 
gelatinosa. 
2.3.2   Muscarinic receptors: Excitatory and inhibitory receptors exist on 
the postsynaptic cell. Both opioid and α2-adrenergic receptors have been 
described on or near the terminals of unmyelinated peripheral nerves. 
  Five Muscarinic receptors subtypes have been cloned. (68) Receptor 
binding studies with non-selective compounds have shown that most 
muscarinic binding sites are localized in the substantia gelatinosa in the 
dorsal horn, and in the motor neuron areas. The area is presumably the one 
involved in antinociceptive effects. The relatively selective M1 and M2 
blocking agents (pirenzepine and FDX 116) both inhibit carbachol-induced 
antinociceptive effect, suggesting that both types of receptors play a role. An 
interaction between adrenergic and cholinergic appears likely. 
Autoradiographic studies reveal the existence of muscarinic receptors; both 
M1 and M2 in lamina 2 and 3 of the SC. Immunohistochemical studies in the 
 rat model have consistently revealed the presence of cell bodies staining for 
choline acetyltransferase in lamina 3, 4 and 5, which are dendritic.  
2.3.3   Clinical application of muscarinic stimulation: 
 Exogenous administered ACh has a very short duration of action 
because it is inactivated rapidly by acetylcholinesterase (at the synapse). 
Nonetheless, the most efficient method for prolonged stimulation of the spinal 
muscarinic system is by the administration of long-acting anticholinesterase, 
which has shown high antinociceptive efficacy and lack of neurotoxicity. 
 Spinal administration of acetylcholinesterase inhibitors, such as 
neostigmine, inhibits breakdown of an endogenous spinal ACh 
neurotransmitter. (69)  
 Release of ACh in the SC is stimulated by pain, systemic opioids, and 
spinal α2-agonists. Further analgesic effects of ACh may involve stimulation 
of production of nitric oxide, as increased level of SC nitrite are observed 
after spinal administration of ACh. Although the nicotinic mechanisms in 
antinociception are more controversial, both types of cholinergic receptors 
have been identified in the nociceptive pathways. As nicely discussed by 
Ping-Heng Tan et al, in this issues, substantia gelatinosa of the human SC is 
especial rich in muscarinic.  
In the spinal cord, concentrations of acetylcholine and noradrenalin, 
and synthesis of nitric oxide (NO) are increased after administration of 
cholinomimetic substances. The former mechanism has been proposed to be 
involved in cholinergic analgesia in acute nociception, such as in 
postoperative pain, while the NO-mediated mechanism would be more 
important in chronic pain after nerve injury. Although it has recently been 
shown that central muscarinic antinociception is highly dependent on the M1 
receptor subtype, analgesia may be induced via stimulation of both 
postsynaptic M1 and presynaptic M2 muscarinic receptors in the brain. (70) 
Another mechanism of analgesia is the muscarinic presynaptic inhibition of 
glutamate secretion. Finally, antinociception and analgesia have been 
 demonstrated by activation of muscarinic receptors in peripheral nerve 
endings. (71) 
In preliminary dose-response studies of neostigmine (6.25, 12.5,and 50 
µg) as an additive to low-dose (7.5mg) bupivacaine anaesthesia conducted in 
volunteers and surgical patients, intrathecal (IT) neostigmine provided 
analgesia in doses  ≥ 10µg (surgical patients "as release of Ach is enhanced 
by pain") to  ≥ 50 µg (volunteers). (72) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.   SPINAL NEOSTIGMINE 
 
Neostigmine consists of a carbamate moiety and a quaternary 
ammonium group. The former provides covalent bonding to 
acetylcholinesterase. The later renders the molecule lipid-insoluble, so that it 
cannot pass through the BBB. (73) 
 
3.1   MECHANISM OF ACTION: 
 Neostigmine is an indirect cholinomimetic agent. It produces its 
primary effects by inhibiting the action of acetylcholinesterase, which 
hydrolyzes ACh to choline and acetic acid. By inhibiting acetylcholinesterase, 
the indirect-acting drug increases the concentration of spinal endogenous 
ACh. 
 This drug is, in effect, amplifiers of endogenous ACh and act primarily 
where ACh is physiologically release. It combines reversibly with 
Acetylcholinesterase by the formation of an ester linkage, witch lasts about 30 
minutes. (74) 
3.2   PHARMACOKINETIC: 
 The pharmacokinetic of neostigmine administered by bolus injection is 
linear with respect to bolus injection. The time of the peak concentration 
ranged from 5-30 min (this the range in time to peak concentration reported 
for pethidine). (75) The absorption phase was followed by a biexponential 
distribution and elimination phase. Diffusion in CSF plays a major role in 
drug distribution.  
There is a sustained plateau of increased ACh concentration in CSF 
after IT neostigmine and lack of correlation between CSF ACh concentration 
and analgesia. It is likely that CSF neostigmine concentration even after the 
lowest dose of neostigmine is an adequate to significantly inhibit 
cholinesterase in CSF. 
 3.3   DOSAGE OF INTRATHECAL NEOSTIGMINE: 
 The effectiveness - reduced pain scores and low consumption of rescue 
analgesics - of subarachnoidally administered neostigmine in doses of 10-100 
µg has been demonstrated in controlled clinical studies. (76) 
3.4   SIDE EFFECTS OF IT NEOSTIGMINE: 
 Intrathecally administered neostigmine could produce side effects by 
local spinal actions (lower extremity weakness, and hypertension) or by 
central distribution (nausea, vomiting and sedation). 
 The incidence and severity of these adverse effects from IT 
neostigmine appears to be affected by dose, method of administration, and the 
baricity of solution. 
 Addition of 50µg neostigmine significantly improve sensory and motor 
block but also lead to delay in achievement of discharge criteria for 
ambulatory anaesthesia and to a high incidence of nausea and vomiting 
(>50%). Addition of even the smallest dose of neostigmine (6.25 µg) 
produced a high incidence of nausea and vomiting (30%) that was sever, 
repetitive, prolonged (2-6 h), and resistance to pharmacologic therapy. 
Intrathecal neostigmine alone produces definitive analgesia in humans. 
In  28 normal healthy human volunteers, IT neostigmine (50-750µg) followed 
by catheter insertion and aspiration of CSF for analysis produce dose-
dependent analgesia accompanied by dose-related  motor weakness, decrease 
in deep tendon reflexes, urinary incontinence, genitourinary stimulation and 
nausea and vomiting. Nausea and vomiting were reduced by injecting it in a 
hyperbaric solution. This study provided the safety basis and defined the side 
effects to be monitored for subsequent clinical trials. 
 Currently available formulations contain the preservatives methyl– and 
propyl–paraben and are usually mixed with glucose to yield hyperbaric 
solutions. The safety of chronically administered IT neostigmine containing 
these additives was examined in animals. (77) Chemically administered IT 
 neostigmine containing glucose and these additives failed to produce 
behavioral, chemical, or histopathological evidence of neurotoxicity. 
In patients undergoing inguinal herniorrhaphy, IT neostigmine 
administered at 50 µg or 100 µg enhance the onset of tetracaine analgesia and 
provide analgesia for a period of about 6-9 hours. Adverse effects such as 
nausea, vomiting, and prolonged motor block were dose dependent. 
In an attempt to evaluate IT neostigmine safety during cesarean section 
(S/C), neostigmine was administered with morphine intrathecally. Fetal heart 
rate (FHR) was monitored for 15 min prior to surgery and during surgery. IT 
neostigmine did not affect FHR in women prior to C/S and was well tolerated. 
It was associated with reduced postoperative morphine requirements, an affect 
that lasts approximately 10 hours. It produced dose-independent reduction in 
morphine use but a trend toward dose-dependent nausea.  
Some studies have revealed that intrathecal neostigmine produced 
dose-dependent analgesia and adverse effects. (78) (79) However, other studies 
have shown that intrathecal neostigmine could produce a dose-independent 
analgesia and a dose-dependent incidence of adverse effects. (80) Efforts, 
therefore, were made to reduce the undesirable adverse effects of IT 
neostigmine.  
Hood et al, demonstrated that IT neostigmine enhanced side effects, 
such as nausea and vomiting, after i.v. opioid administration (alfentanyl). (81) 
Both IT neostigmine and i.v. alfentanyl increased CSF ACh concentrations 
and produced analgesia. Neostigmine didn't enhance respiratory depression 
induced by i.v. alfentanyl, although it does enhanced sedation and nausea.  
A study was designed to compare the effects of the addition of IT 
neostigmine or IT morphine on the characteristics of SA with bupivacaine. (82) 
IT 300 µg morphine produced long lasting analgesia with duration of about 
10 hours compared to IT 50 µg neostigmine which resulted in postoperative 
analgesia lasting about 7 hours. The incidence of adverse effects was similar 
 for the two groups, except for pruritus, which occurred more frequently in the 
morphine group.  
 Involuntary defecation during the postoperative period was reported 
as an adverse effect with production of poor analgesic effects in patients 
suffering from ischemic pain or in patients undergoing cesarean section and 
orthopedic surgery under spinal anaesthesia. (83)  
 Vomiting was not observed following intra-operative spinal 
administration of neostigmine in patients under enflurane anaesthesia. (84)  
The incidence of vomiting and hypotension was reduced in volunteers treated 
intrathecally with a hyperbaric solution of neostigmine. 
 The effect of a prophylactic single dose of i.v. dexamethasone (10mg) 
injection on the incidence and severity of postoperative nausea and vomiting 
after IT injection of tetracaine plus neostigmine 100 µg was evaluated. (85) It 
was found that, it didn't reduce the incidence of emesis in patients receiving 
SA during inguinal herniorrhaphy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.   LOCAL ANAESTHETICS 
 
Regional anaesthetic techniques depends on a group of drugs that 
produce transient reversible loss of sensory, motor, and autonomic function in 
a discrete portion of the body. 
4.1   CLASSIFICATION AND STRUCTURE-ACTIVITY 
RELATIONSHIPS: 
 
Local anaesthetics consist of a lipophilic group – usually a benzene 
ring (aromatic ring) - separated from a hydrophilic group -usually a tertiary 
amine- by an intermediate chain that includes ester or amide linkage. Local 
anaesthetics are weak bases that are usually carrying a positive charge at the 
tertiary amine group at physiological pH. 
The nature of the intermediate chain is the basis of the classification 
of Local anaesthetics as esters or amides. Physiochemical properties of Local 
anaesthetics depend on; 
? The substitutions in the aromatic ring, 
? The type of linkage in the intermediate chain, and 
? The alkyl groups attached to the amine nitrogen. 
Potency correlates with lipid solubility, and depends on the ability of 
the Local anaesthetic to penetrate a hydrophobic environment. 
Onset of action depends on many factors, including, the relative 
concentration of non-ionized lipid-soluble form and the ionized water soluble 
form. 
Duration of action is associated with plasma protein binding (α1-acid 
glycoprotein). 
 
 
 
 4.2 MECHANISM OF ACTION: 
 They block the initiation and propagation of action potential by 
blocking the voltage-dependent sodium channels. They bind to specific 
receptors on the inner surface of sodium channel. (86) 
 Local anaesthetics are weak bases and at physiological pH, both 
charged forms exist (depending upon the pKa of Local anaesthetics which is 
usually 8-9). The free un-dissociated base (lipophilic) penetrates the nerve 
sheath and axonal membrane to reach its site of action. The cationic (charged; 
hydrophilic) form is probably responsible for the sodium-channel blockade. 
Quaternary local anaesthetics block the channel from inside 
(hydrophilic pathway). They reach their site of action via an open channel.  
Tertiary or secondary amine Local anaesthetics penetrate the sheath and 
axonal membrane in the uncharged form (lipophilic pathway) to block the 
channel. However, they can also act from the inner surface of the membrane 
if they are in the cationic form. 
Small diameter unmyelinated fibers are most susceptible then large 
myelinated ones. Pain sensation is abolished first, followed by cold, warmth, 
touch and pressure. 
Local anaesthetics solution injected into the CSF spreads away from 
the site of injection and the concentration of the solution decreases as mixing 
occurs. A differential blockade of fibers occurs because small fibers are 
blocked by weaker concentrations of Local anaesthetic solution. 
4.3   LOCAL ANAESTHETICS USED IN SPINAL 
ANAESTHESIA: 
 The choice of Local anaesthetic for a specific procedure is usually 
based on the duration of action (surgery) required. Procaine is short acting; 
lidocaine has an intermediate duration of action; tetracaine, bupivacaine, and 
ropivacaine are long-acting drugs. 
 
 
 4.3.1   Procaine: 
Procaine is the oldest member of the ester Local anaesthetic family 
(1904) and still remains in clinical use. 
 The synthesis of procaine for peripheral nerve block was coincident 
with the first attempts at achieving anaesthesia in the subarachnoid space, and 
procaine was one of the first Local anaesthetics used for SA.  
 It is a water-soluble agent with poor lipid solubility. Toxicity with 
procaine is very uncommon, unless massive doses are administered or large 
doses are injected directly into the blood stream.  
SA can be performed with 50-200 mg of the 10% solution of procaine mixed 
with equal volumes of 10% glucose, or as the lyophilized crystal diluted in 
glucose or CSF . The duration of subarachnoid block would be 30-60 min. 
procaine has been mixed with tetracaine or lidocaine for SA for c/s to 
accentuate the density of the block in the past to achieve an improved quality 
of SA.  
4.3.2   Lidocaine: 
The discovery in 1948 by Lofgren in Sweden of lidocaine began the 
aminoamide era. Lidocaine proved to be excellent introduction for the amide 
agents because of its versatility, clinical efficacy, and reasonable clinical 
toxicity range. In the subarachnoid space, rapid complete anaesthesia is 
achieved with an intermediate duration.  
 Lidocaine is the most commonly selected agent for short-duration SA. 
Lidocaine is used for SA in the 2-5% range, either as isobaric or hyperbaric 
solutions. The most common preparation of lidocaine for SA is a pre-mixed 
hyperbaric solution of 5% in 7.5% glucose. When 50 - 75 mg are injected 
into the average-sized adult, rapid onset of dense and complete motor block 
occurs, which lasts for 60-90 min. this can be prolonged  20-30% by the 
addition of epinephrine . When concentration is reduced to 1.5% lidocaine 
with the same concentration of dextrose, the clinical outcome is 
indistinguishable. (87) For isobaric lidocaine SA, 2-3ml of the 2% solution are 
 injected, which result in a slightly slower onset of comparable anaesthesia 
with a slightly  longer duration. (88) This can be explained by the delayed peak 
level in the plasma and delayed elimination half-life from the subarachnoid 
space compared to the hyperbaric solution. Lidocaine can be diluted with 
sterile water for a hypobaric application. 
 Active controversy exists about whether lidocaine is neurotoxic in the 
subarachnoid space or whether the concentration (5%) may be the etiology. 
Cases of cauda equina syndrome have been associated with 5% lidocaine with 
continuous SA and less frequently, with single-shot SA. (89) (90) 
4.3.3   Tetracaine: 
Tetracaine is an ester local anaesthetic belonging to the procaine group. 
It is a chemical derivative of procaine with higher lipid solubility (100 times 
than procaine), potency, and duration of anaesthesia. Release of tetracaine led 
to its rapid acceptance as the most popular agent for SA; which it remains. It 
is the agent most commonly used for SA in the US.  
 The 1% solution is included in most commercial available trys for SA. 
The 1% solution is mixed with equal volumes of 10% dextrose for hyperbaric, 
with preservative-free sterile water for hypobaric and with the patient's CSF 
for an isobaric SA. 
 When 0.5% tetracaine is used for isobaric SA, complete motor block 
and duration of anaesthesia of 180 minutes or longer is achieved. In contrast 
to bupivacaine SA, a dense, long-acting motor block is achieved with 
tetracaine. 
4.3.4   Bupivacaine: 
Bupivacaine was created by modification of an existing local 
anaesthetic (mepivacaine) with intent to create a more potent, longer local 
anaesthetic. (91) The duration of action of bupivacaine exceeds lidocaine by a 
two to three times or more. Limited placental transfusion combined with the 
selective increased potency for sensory block and relatively decreased 
 potential for motor block at lower concentration, established efficacy for 
obstetric anaesthesia.  
 At very low concentrations (< 0.25%), sensory anaesthesia and 
analgesia separate and achieving analgesia without complete motor block is 
possible and is used extensively for acute postoperative pain control. 
 Bupivacaine is commonly selected for SA .the atypical dose is 15mg of 
bupivacaine, prepared as 3 ml of 0.5% plain bupivacaine. Epinephrine 
accentuates the intensity of the block, especially the motor block, but has no 
influence on the duration of the block. The duration of bupivacaine SA is 
comparable to tetracaine (150-180 mints), and it is longer in geriatric patients. 
Dilution and reduction of the total dose of hyperbaric bupivacaine reduced the 
duration of the block by 50% and reduced the total time to release from an 
ambulatory unit by >50%. (92) 
4.3.5   Ropivacaine: 
Ropivacaine is the newest addition to the clinical options of regional 
anaesthesia. It is similar chemically to bupivacaine. Preliminary work 
suggests that ropivacaine has lower potency and shorter motor block in the 
subarachnoid space than bupivacaine with a greater degree of differential 
block in dilute solutions. (93) At equivalent concentrations ropivacaine 
appears to be less likely than bupivacaine to cause cardiac arrhythmias and 
collapse; resuscitation is more likely than successful if toxicity does occur. 
 
 
 
 
 
 
 OBJECTIVES 
 
The present study is designed to: 
♦ Evaluate the effects of the addition of different doses of 
neostigmine on the characteristics of spinal anaesthesia using 
bupivacaine and to, 
♦ Assess their postoperative analgesic efficacy and safety in 
patients undergoing infra-umbilical surgery under spinal 
anaesthesia. 
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PATIENTS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PATIENTS AND METHODS 
 
1.  HOSPITALS AND PERIOD OF STUDY: 
 This study was performed at KHARTOUM teaching hospital (KTH) 
and SOBA university hospital (SUH). The well equipped theatres and the 
facilities of observation and follow up the patients were the main reasons for 
selecting these hospitals. The study extended from 1st of March 2003 to 15th 
February 2004. 
2.  STUDY DESIGN: 
 The study protocol was approved by the medical committee of our 
university department and hospitals. Written informed consents were taken 
from all patients. Sixty Sudanese ASA 1-2 patients, scheduled for elective 
infra-umbilical surgery under spinal anaesthesia were included in this study. 
 This is a prospective comparative study in which the effects of different 
doses of neostigmine on the characteristics of SA were studied and compared. 
Patients were allocated randomly into one of three groups, each group was 20 
patients:  
? Group 1 received hyperbaric IT bupivacaine (0.5%) 15 mg + 0.5 ml 
dextrose (5%). 
? Group 2 received hyperbaric IT bupivacaine (0.5%) 15 mg + IT 
neostigmine (50µg) diluted in 0.5 ml dextrose (5%). 
? Group 3 received hyperbaric IT bupivacaine (0.5%) 15 mg + IT 
neostigmine (100µg) diluted in 0.5 ml dextrose (5%). 
3.  INCLUSION CRITERIA: 
? Patients of fitness rating of ASA grade 1 and 2. 
? Co-operative patients. 
 ? Patients undergoing elective surgical procedure under SA and who were 
planned to maintain a supine position throughout the surgery. 
4.  EXCLUSION CRITERIA: 
? Patients at age < 20 years and > 70 years. 
? Patients of ASA grade >2. 
? Deaf and dumb patients or both. 
? Patients with allergies to any of the test drugs. 
? Patients in whom there was absolute or relative contraindication to SA. 
? Prolonged surgery in which the patients received any of general 
anaesthesia support. 
? Presence of preoperative nausea or vomiting. 
? Pregnant patients or planned for cesarean section. 
? Patients who have received any pre-medications. 
5.  PATIENT INTERVIEWS: 
 General characteristics of patients, obtained from history and 
examination, were recorded in a special designed form. Personal data;  name, 
age, and sex, baseline vital signs (pulse, BP, and respiratory rate), ASA grade, 
time of onset of anaesthesia and kind, onset, and duration of operation were 
recorded. 
 All patients were inquired about their past medical, surgical, and 
anaesthetic history and whether the patient has experienced any complications 
following a previous anaesthetic exposure. Agents taken or allergy to any 
were asked about and checked. 
 A full physical examination was conducted to all subjects with 
emphasis on the cardiovascular, respiratory, CNS, lumbar site and airway 
assessment. Routine preoperative investigations were observed. 
 6.  PREPARATION BEFORE CONDUCTION OF SPINAL 
ANAESTHESIA: 
 In the holding room, an explanation of the procedure and its benefits 
was given. An i.v. line was inserted into the forearm using 18-gauge i.v. 
cannula, and all patients were given 500 ml of normal saline (0.9) solution as 
a circulatory preload. 
 Materials necessary for aseptic performance of drug dilution and SA 
were prepared. 
 Resuscitation equipments and drugs were prepared and kept within 
reach. Insulin 1ml syringe was used to make precise dosing. 
7.  CONDUCTION OF SPINAL ANAESTHESIA: 
 Spinal anaesthesia was performed in the operating room at the L3-L4 
interspace with the patient in the sitting position. 
? The back was exposed, scrubbed using savlon and sterilized with spirit. 
? Infiltration of skin and subcutaneous tissue over the interspace chosen 
were done by 3 ml of 2% lidocaine. 
? A 0.5 mg neostigmine methyl sulphate was withdrawn into a sterile 5 ml 
syringe, then diluted to a total of 5 ml of dextrose (5%) in group 2 (0.5 ml 
= 50µg neostigmine), or  to 2.5 ml  in group 3 (0.5 ml = 100µg 
neostigmine). 
? A 0.5 ml of the diluted neostigmine was withdrawn into an insulin syringe 
and added to the 3 ml hyperbaric bupivacaine (15 mg). 
? A sterile disposable 22-gauge spinal needle was then slowly introduced 
until dura was puncture and free backflow of CSF checked. 
? The premixed drug was then injected slowly; over duration of 
approximately 30 seconds. 
 ? The puncture site was covered by sterile gauze that was held in place by 
means of adhesive Elastoplasts. 
? The patients were positioned horizontally in the supine position and they 
were kept at the same position throughout surgery. 
8.  MONITORING AND ASSESSMENT OF PAIN AND OTHER 
OBSERVATIONS: 
 Non-invasive measurement of BP,  PR, RR and oxygen saturation 
(Spo2) were monitored, every 3 minutes for the initial 15 minutes, then every 
5 minutes throughout the surgery, and then, except, Spo2, every 3o minutes in 
the postanaesthesia care unit (PACU) for 2 hours. Bradycardia (PR < 6o beat 
/minutes) was treated with i.v. atropine (0.5 mg). IVF boluses and incremental 
doses of ephedrine (5mg) were given to those patients whose systolic BP fell 
below 100 mmHg. 
Observation of retching was used to evaluate adverse effects (e.g. 
nausea, vomiting, and sedation). Nausea was scored by the patient using the 
10-cm visual analogue score (VAS) (0-10). Nausea that scored greater than 2 
of the VAS at any time, or vomiting, more than once, was treated initially 
with i.v. 10 mg Metoclopramide followed by Ondansetron 4 mg IV, if 
necessary. The number of patients having nausea (at any degree) or vomiting 
(at any point) intra-operatively was noted and recorded. 
 The level of sensory block was tested by pinprick, and the sensory level 
at 5 and 10 minutes intervals, after drug injection, were recorded.  
 The severity of postoperative pain was measured using a 10-cm VAS (0 
= no pain, 10 = the worst possible pain). The 24 hour VAS score reflected the 
patient's assessment of total pain experience for the previous 24hour post-
intrathecal drug administration. 
The duration of absolute analgesia was measured from the time of drug 
administration to the time when the VAS-pain score was greater than zero. 
 The time of administering the first dose of diclofenac for postoperative pain, 
and the number of diclofenac administered were, also recorded. The 
postoperative analgesia was provided with IM diclofenac 75 mg if the VAS 
score was ≥ 4 and can be repeated 8 hourly as necessary. 
The duration of motor block was assessed using the Bromage scale and 
was recorded from the time of drug administration to the time when patients 
able to lift their legs in bed, against gravity (grade 2). 
Respiratory depression was defined by a RR < 10 breaths/minutes. 
Scores of postoperative pain, any side effect, and patient evaluation were 
recorded at 4 hours interval for 24 hours post-IT drug administration. 
9.  METHODS OF DATA COLLECTION: 
 The following techniques and tools were used; 
? Scheduled observation form. 
? The severity of postoperative pain is measured using a 10 cm VAS, during 
rest 4 hourly or whenever patient requested analgesia. 
?  Assessment of the level of sedation was made intra-and postoperatively 
using an objective score based on eye opening (eyes open spontaneously = 
0, in response to speech = 1, and in response to physical stimulation = 2). 
? the Bromage scale was used to evaluate the duration of motor blockade: 
“no block" (the ability to flex the knees and feet), “partial block” (ability 
to flex the knees and resist gravity with full, movement of the feet), 
“almost complete block” (inability to flex the knees but retained ability to 
flex feet), and “complete block” (inability to move the legs or feet). 
? Nausea was scored by the patient using the 10-cm VAS-N score, which 
consists of a 10-cm line, with 0 equaling 'no nausea' and 10 equaling 'worst 
possible nausea'. 
 
 10. DATA ANALYSIS: 
 The data collected were analyzed and compared by analysis of variance 
with paired-samples T test using a manual master sheet and SPSS software 
program. Data were expressed as means ± standard deviation of the mean or 
median and the (25th-75th) percentile confidence interval as appropriate. A 
value of p<0.05 was regarded as a statistically significant differences. 
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 RESULTS 
 
Sixty patients were included in this study, twenty in each group. The 
three groups showed no differences regarding ASA physical status, age, sex, 
preoperative vital signs, and surgical time (p >0.05) (Table 1) (Fig. 1, 2, 3). 
 The onset of anaesthesia, as measured by the level to pinprick at 5 and 
10 minutes, was significantly earlier for group II and III patients. Median 
values (25%–75% percentile confidence) of thoracic (T) dermatome to a 
pinprick on the skin were being T8 (7–9) for group II and T8 (7–8) for group 
III compared with the median value for group I patients T10 (9–10.7) at 5 
minutes (P  <0.05). At 10 minutes, it was T6 (4–6) for group II patients and 
T5 (5–5) for group III patients compared with the median for group1 patients 
T7 (5–8) (p < 0.05). However the difference between group II and III was not 
significant at 5 minutes (p=0.287) (Table 2) (Fig. 4). The three groups 
showed no differences regarding intraoperative data. (Fig. 5) 
The duration of absolute analgesia, which was measured between the 
time of drug administration to the time when the VAS pain score was greater 
than zero, group III patients showed a much longer duration of complete 
analgesia with an average of 6 ±1.4 hours, compared to 3.5 ± 1 hours for 
group I patients (p < 0.001) and 4.7 ±1.4 hours for group II patients (p = 
0.017) (Table 3) (Fig. 6, 7). 
The mean time until the first dose of  IM diclofenac administration was 
longer for group III patients (7.7 ± 2.1 hours) compared with group I patients 
(4.9 ± 1.3 hrs) ( p < 0.001) and group II patients (6.3 ± 1.8 hrs) ( p=0.045) 
(Table 4) (Fig. 8). 
Again comparing group I and group III patients, there was a significant 
difference in the number of IM Diclofenac injections requested in the 24 hr 
post surgery (Fig. 9). The median number of injections for group I, group II, 
 and group III patients was, respectively, 2.5(1.25–3), 1(1–1), and 1(1–3) and 
P was less than 0.05 between all groups. All patients of group I (100%) 
needed postoperative analgesia and the time of rescue analgesia 
administration ranged from (2.1–7.6 hours) postoperatively. In group II 
patients, 13 (65%) needed postoperative analgesia. The time of rescue 
analgesic administration ranged from (3–11.4 hrs). In group III patients, 18 
(90%) needed postoperative analgesia and the time of rescue analgesic 
administration ranged from (4.5–12.6 hrs) postoperatively. 
Intraoperative hypotension (systolic BP < 100 mmHg or a decrease in 
systolic BP >20% below preanaesthetic baseline) was recorded in 9 patients 
in group I (45 %), in 8 patients in group II (40%), and in 3 patients in group 
III (20%). This difference in incidence between the three groups was not 
significant (p > 0.05) (Fig. 10). There was no significant differences in the 
total i.v. ephedrine injections requested intraoperatively (p > 0.05) (Table 5). 
Three patients in group I (15%) had Intraoperative bradycardia 71.6 
minuets (40 – 95) after the spinal injection (Table 6). Four patients in group 
II (20%) had Intraoperative bradycardia 57.5 minutes (15 – 95 min) after the 
spinal injection. Two patients in group III (10%) had Intraoperative 
bradycardia 90 minuets (30 – 150) after the spinal injection. This difference in 
incidence between the three groups was not significant (p > 0.05). All were 
being treated with i.v. atropine 0.5 mg increments. There was significant 
differences in the total i.v. atropine injections requested intraoperatively (p < 
0.05) (Fig. 11). 
The Intraoperative VAS–Nausea and time to first episode of nausea or 
occurrence of vomiting were different among the groups (Table 7). Nausea 
was recorded in 5 patients in group I (25%), in 7 patients in group II (35%), 
and in 4 patients in group III (20%) (Fig. 12). 
 There was significant difference in the time to first episode of nausea 
between group II and group III compared with group I (p < 0.001) and 
between group II and group III (p=0.026) (Fig. 13). 
Patients in group II and  group III demonstrated a highly significant 
increase in the severity of nausea compared with group I, means of VAS–
Nausea score were 10.5 ±2.1 and 10.5 ±2.1  for group II and group III, 
respectively,  compared with 2.4 ±0.2.5 for group I (p < 0.001). However, the 
difference between group II and group III was not significant (p = 0.239). 
(Fig. 14) 
Patients in group II and group III demonstrated a significant increase in 
the incidence of vomiting compared with group I (p < 0.05). However, 
patients in group II showed a significantly higher incidence in severity of 
vomiting than those in group III (p < 0.05) (Table 8). 
None of patients in group I required any treatment for nausea and 
vomiting. In group II patients, 5(25%) of them needed i.v. metoclopramide 
(10mg) injection and then, 3(15%) of them required supplement with i.v. 
Ondansetron (4mg). In group III patients, 4(20%) needed i.v. metoclopramide 
(10mg) injection and then, 3(15%) of them required supplement with i.v. 
Ondansetron (4mg) (Fig. 15). 
Motor block was significantly prolonged for group III patients (5.8±1.6 
hr) compared with group I participants (4.3±1.5 h) (p =0.002). However, the 
differences between group I patients and group II patients (4.8±1.9 h) and 
between group II and group III patients were not significant (p = 0.150 and 
0.16, respectively) (Table 9). 
One patient from each group, group II and III, had a bowel movement 
150 minutes and 120 minutes, respectively, after the spinal injection (Table 
10). 
None of the patients had any episodes of motor weakness. Sedation 
scores were comparable in all the groups. No patient had a sedation score of 
 more than 0 at any time. No delayed adverse effects were observed during the 
postoperative follow up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLES 
 
Table (1): 
 
Demographic data of the patients  
Group I II  III  
Number 20 20 20 
Age (yr) 50.5 ±16.3 48.9 ±16.3 44.9 ±15.3 
ASA (1:2) 18/2 20/0 20/0 
Sex (M: F) 15/5 11/9 13/7 
Surgical time (min) 88.2 ±37.1 94.7 ±36.1 84.3 ±35.7 
Respiratory rate (min) 19.9 ±3.2 18.8 18.6 ±1.6 
Pulse rate (min) 91.4 ±18.8 94.7 ±15.6 100.3 ±20.5 
BP (mmHg) 92.8 ±10.8 91.6 ±12.4 96.5 ±14.8 
Oxygen saturation (%) 97.9 ±1.3 97 ±18.1 98.1 ±1.2 
Note: Data are expressed as mean ± SD.  
No statistically significant differences were observed (p > 0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
Table (2):  
  
Level to pinprick at 5 and 10 minutes  
Group I II  III  
Number 20 20 20 
Pinprick (5 min)* 10(9 - 10.7) 8(7 - 9) 8(7 - 8) 
Pinprick (10 min)* 7(5 - 8) 6(4 - 6) 5(5 - 5) 
Pinprick: the thoracic dermatome anaesthesia to a pinprick on the skin. 
*Median (25% - 75% percentile confidence). 
 
 
 
 
 
 
 
 
 
 
 
  
Table (3): 
  
Postoperative analgesia  
Group I II  III  
Number 20 20 20 
 
Duration of absolute analgesia (hrs)^ 3.5 ±1* 4.7 ±1.4* 6 ±1.4* 
 
Overall 24-hour VAS pain+ 19.6 ±6.4* 12.5 ±3.1* 10.2 ±2.6* 
* Note: Data are expressed as means ± SD. 
^ P = 0.003, group 1 versus group 2, p < 0.001, group 1 versus group 3, p = 0.017, group 2      
versus group 3.  
+ P < 0.005 
 
 
 
 
 
 
Table (4): 
 
Need for postoperative analgesia 
Group I II  III  
Number 20 20 20 
 
Time to first rescue analgesia 
(hrs)^ 4.9 ±1.3* 6.3 ±1.8 7.7 ±2.1 
No. of patients Received 
diclofenac injection 20(100% 13(65%) 18(90%) 
Number of IM diclofenac dose 
injection for each patient in 24 hª 
 2.5 (1.25 – 3) 1(1 – 1) 1(1 – 2) 
* Note: Data are expressed as means ± SD. Other data are expressed as Median (25% - 
75% percentile confidence). 
^ P = 0.01, group 1 versus group 2, p < 0.001, group 1 versus group 3, p = 0.045, group 2      
versus group 3.  
ª P < 0.001, group 1 versus group 2, p = 0.001, group 1 versus group 3, p = 0.004, group 2      
versus group 3. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table (5): 
 
Intraoperative hypotension  
Group I II  III  
Number 20 20 20 
No. of patients developed 
intraoperative hypotension (%) 9(45%) 8(40%) 4(20%) 
 
Onset to first hypotension 
(min)* 
 
Total intraoperative ephedrine 
injection (mg)* ^ 
34.7 ±29.7 
 
20 ±.7 
31 ±19.5 
 
21.25 ±6.6 
22.7 ±14 
 
25 ±9.4 
*Note: Data are expressed as means ± SD. 
^p > 0.05 
 
 
 
 
 
 
Table (6): 
  
Intraoperative bradycardia 
Group I II  III  
Number 20 20 20 
No. of patients developed 
intraoperative bradycardia 
(%) 
 
3(15%) 4(20%) 2(10%) 
Onset to first bradycardia 
(min)* 
 
Total intraoperative 
atropine injection* ^ 
71.6 ±28.4 
 
1 ±0.16 
57.5 ±38.6 
 
0.75 ±0.1 
90 ±84.8 
 
0.5 
* Note: Data are expressed as means ± SD. 
^P < 0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table (7):  
  
Intraoperative Nausea    
Group I II  III  
Number 20 20 20 
No. of patients having nausea 
per total of patients 5/20 (25%) 7/20 (35%) 4/20 (20%) 
    
Time to first nausea (min)^ 213 ±60 115 ±63 63.7 ±37 
    
Overall 24-hourVAS nausea^ 2.4 ±0.24 10.5 ±2.1 10.5 ±2.1 
    
No. of metoclopramide 
(10mg) injections 0 5/20(25%) 4/20(20%) 
    
No. of ondansetron (4mg) 
injections 0 3/20(15%) 3/20(15%) 
^Note: Data are expressed as means ± SD. 
 
 
 
 
 
 
Table (8): 
 
Intraoperative Vomiting 
Group I II  III  
Number 20 20 20 
No. of patients having 
vomiting per total of patients 1/20 (5%) 2/20 (10%) 3/20 (15%) 
    
Median number of vomiting* 1(1 - 1) 10.5(9 - 12) 2(21 - 3) 
*Median (25% - 75% percentile confidence). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table (9):  
  
Motor block 
Group I II  III  
Number 20 20 20 
Motor block duration (hr)* 4.37 ±1.5 4.8 ±1.9 5.8 ±1.6 
*Note: Data are expressed as means ± SD. 
P = 0.150, group 1 versus group 2, p = 0.002, group 1 versus group 3, p = 0.164, group 2      
versus group 3. 
 
 
 
 
 
 
 
 
 
 
Table (10): 
 
Bowel movement   
Group I II  III  
Number 20 20 20 
No. of patients developed 
bowel movement (%) 0 1(5%) 1(5%) 
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 DISCUSSION 
 
 In phase I study assessment of intrathecal neostigmine in humans, 
Hood et al. found that broad range of intrathecal neostigmine from 150 – 500 
µg could be safely used. When translated to per kg dosage in a 75-kg subject 
in their study, this corresponds to 2 – 7 µg/kg of intrathecal dose. In a study in 
patients undergoing orthopedic procedures involving use of epidural 
neostigmine, Lauretti et al. have taken into account the polar nature of 
neostigmine and thereby suggested that the extradural route can safely use 10 
times the dose of intrathecal Neostigmine. Thus, the extradural dose equates 
to approximately 20 – 70 µg/kg. In a study in paediatric patients undergoing 
genitourinary surgery involving the use of caudal neostigmine, Batra et al. 
used caudal neostigmine in a dose range of 10 – 50 µg/kg. (94) 
Considering the safe use of high doses of  neostigmine by intrathecal, 
epidural and caudal routes, and based upon Hood's and other experiences , we 
chose to used intrathecal neostigmine at a dose of 50 µg and 100 µg for our 
clinical study. 
  Dose dependent analgesia with neuraxial administration of neostigmine 
was well known in animal and human tested. Hood et al. in an open label dose 
ranging study of intrathecal neostigmine revealed dose dependent-analgesia 
in humans with dose greater than 100 µg/kg . 
Lauretti et al. in their study in patients undergoing vaginoplasty 
demonstrated that increasing doses of intrathecal neostigmine from 50 – 200 
µg in combination with intrathecal morphine produced a dose-dependent 
pattern of analgesia, which allowed a reduction in the dose of each 
component. Tan and co-workers have also demonstrated dose-dependent 
analgesic effect of intrathecal neostigmine postinguinal herniorrhaphy. At the 
 same time, Nakayama et al. have demonstrated the dose-dependent analgesic 
effect of epidural neostigmine after abdominal hysterectomy. (95) 
However, other studies have shown dose-independent effect of 
neuraxial administration of neostigmine on postoperative pain relieve and 
analgesic requirement. In pregnant patients, Krukaowski et al. have 
demonstrated that lower doses of intrathecal neostigmine (10, 30, and 100 µg) 
produced dose-independent analgesia lasting approximately 10 h in all the 
three groups. Similarly Lauretti et al. have shown dose-independent analgesia 
in patients undergoing vaginal hysterectomy in a dose range of 25 – 75 µg/kg 
Neostigmine. Same authors also demonstrated dose-independent analgesia 
with a combination of 20 mg intrathecal bupivacaine and 85 mg epidural 
lignocaine and intrathecal neostigmine (1, 2, or 4 µg/kg) in patients 
undergoing knee surgery. 
Various studies with intrathecal or epidural neostigmine have also used 
neuraxial opioids.(96)(97) Lauretti et al. demonstrated that, the combination of 
25 µg of neostigmine with 25 µg fentanyl given intrathecally prolonged the 
time to first rescue medication (< 5 hours) and resulted in smaller number of 
IM Diclofenac injections in 24 hours. 
 In vitro and in vivo studies in animals have reported the release of 
spinal acetylcholine (ACh) in response to morphine. Opioids are known to 
stimulate norepinephrine and ACh release in the dorsal horn of spinal cord 
and thereby potentiate the effect of neostigmine. (98) Dose-dependent increase 
in CSF norepinephrine and ACh has been demonstrated in sheep and man 
after intravenous opioids. This spinally released norepinephrine is believed to 
act on α2-adrenoceptors on spinal cholinergic neurons to cause ACh release. 
  Our study did not involve use of any systemic or neuraxial opioids and 
therefore simply represents a dose response curve to the increasing doses of 
spinal neostigmine. Our result was consistent with Hood's et al and Tan et al. 
A significant prolongation of postoperative complete analgesia and the time 
 for the first dose of diclofenac was seen with increasing doses of neostigmine 
from 50 – 100 µg compared with control group. The duration of complete 
analgesia increased from 4.7 ±1.4 h with 50 µg neostigmine to 6 ±1.4 h with a 
dosage of 100 µg compared to 3.5 ±1 h with bupivacaine alone. Not only did 
the postoperative analgesia increased but also the total analgesic requirement 
and number of rescue doses of analgesic decreased with increasing doses of 
spinal neostigmine. 
 The intrathecal administration of cholinergic receptor agonists or 
cholinesterase inhibitors produces an antinociceptive effect, which is 
mediated by spinal muscarinic receptors in animals, this analgesia have also 
been confirmed in human studies. (99) 
 Studies demonstrated the existence of muscarinic receptors, both M1 
and M2, in laminae 2 and 3 of the spinal cord. Immunohistochemical studies 
in the rat model have consistently revealed the presence of cell bodies staining 
for choline acetyltransferase in laminae 3, 4 and 5, which are dentritic, 
arborized to laminae 1, 2, and 3 that predominantly process afferent 
nociceptive impulses. These results indicate that the muscarinic cholinergic 
system of the lumbar spinal cord is intrinsic. Intrinsic spinal cholinergic 
terminals are presynaptic to primary afferents. Taken together, these studies 
provide strong evidence for processing of afferent impulses of the intrinsic 
spinal cord cholinergic system. It has been suggested that acetylcholinesterase 
inhibitors act on the ACh released from those intrinsic spinal terminals.  
 Neostigmine, an anticholinesterase inhibitor, may cause an 
accumulation of ACh at the muscarinic receptors in the dorsal horn when 
administered intrathecally. Thus, increased spinal levels of ACh may augment 
antinociceptive effect as a result of axonal conduction block from spinal 
bupivacaine. Such an additive effect has previously been reported. In our 
study, the more rapid onset and spread of anaesthesia, as measured by the 
level of sensory block at 5 and 10 minutes, was significantly earlier after 
 spinal bupivacaine when combined with spinal neostigmine. At the same 
time, the increased duration and quality of analgesia for group III patients 
compared with group I values, revealed an additive effect of the combined 
administration of intrathecal neostigmine and bupivacaine. 
 Hypotension and bradycardia are common side effects of spinal 
anaesthesia, and they represent normal physiologic responses to anaesthetized 
spinal sympathetic nerve fibers. The primary physiologic alteration is 
decreased preload, which combines with bradycardia to reduce arterial blood 
pressure and cardiac output. Mild hypotension or bradycardia may be treated 
with volume expansion, ephedrine, or atropine. However, severe and/or 
rapidly progressing bradycardia demands aggressive treatment with 
epinephrine, followed by cardiopulmonary resuscitation if appropriate. 
In our study, the difference in incidence of Intraoperative hypotension 
and bradycardia between the three groups was not significant, i.e. addition of 
neostigmine to bupivacaine (in group II and III) did not increase significantly 
the incidence of intraoperative hypotension and bradycardia than that which 
was recorded in group I (bupivacaine only). 
To minimize the effect of sudden sympathetic block, a preload of 500 
ml of normal saline was completed prior to instituting the block in our 
patients. Some recent studies suggested that intravenous prehydration does 
not prevent hypotension, but may reduce its incidence, irrespective of the 
volume infused or of the use of colloids versus crystalloids (100) (101). 
Gradual heart rate reduction that stabilizes within 10% to 15% of 
baseline and is not associated with hypotension requires careful observation 
but may not require treatment. Similarly, 15% to 20% reduction of arterial 
blood pressure in healthy patients without pre-existing hypertension, coronary 
artery disease, or aortic stenosis is not necessarily associated with 
compromised end-organ blood flow. Intrathecal Injection of the drugs was 
given slowly to avoid development of severe hypotension, as one study 
 concluded that a 2 ml/min injection rate might be a simple and effective way 
to reduce the incidence and severity of hypotension during caesarean section 
under spinal anaesthesia. In our study, those who developed hypotension were 
managed by increase the rate of normal saline infusion with incremental doses 
of ephedrine and those who developed bradycardia were given atropine. 
Postoperative hypotension and bradycardia was not recorded in any patient of 
the three groups. 
 Neostigmine preparations used in the patient study included methyl- 
and propyl-parabens as preservatives. Early experimental and clinical trials 
used preservative-free Neostigmine.(102) Although preservative-free is not 
associated with neurotoxicity, it is no longer marketed. Two investigations 
have confirmed that chronically administered intrathecal neostigmine 
containing methyl- and propyl-parabens in glucose-containing solution is not 
associated with any behavioral, chemical, or histopathological evidence of 
neurotoxicity.(102) Tan and co-workers in the subsequent outpatient follow-up 
reviewed neurological sequelae, including persistence parasthesia, sensory or 
motor deficits, and bowel or bladder dysfunction. None of the patients in that 
study developed short-or long-term neurological impairment or deficit during 
a 1-year follow-up period. 
 Despite its proven analgesic effectiveness, neuraxial neostigmine is not 
yet a widely accepted analgesic modality in clinical practice and continues to 
be an off-label indication. This is mainly because of the frequent incidence of 
nausea and vomiting. In a dose-response study, an intrathecal neostigmine 
dose, range of 6.25 – 50 µg, was associated with a relatively frequent 
incidence of nausea (33% - 67%) and vomiting (17% - 50%).  
Reducing the dose to 10µg, the injection of neostigmine in a hyperbaric 
dextrose solution, and maintaining the patient in head-up position in patients 
receiving spinal neostigmine are effective measures in reducing the incidence 
of nausea and vomiting. This was explained by minimizing cephalad spread 
 and, presumably, subsequently reduces the incidence of nausea and vomiting. 
Probably the epidural route of administration of neostigmine may eventually 
prove superior to the intrathecal route with respect to the incidence of 
associated nausea and vomiting. (103) (104) 
In present study, we also observed a significantly higher intraoperative 
VAS-nausea and increased incidence of vomiting associated with intrathecal 
neostigmine at doses of 50 µg or 100 µg, in a dose-dependent manner with a 
significant number of patients requiring treatment. Maximum episode of 
nausea and vomiting occurred at 115 ± 63 min and at 63.7 ± 37 min in group 
II and III patients, after the study drug injection and this is consistent with 
previously reported delay of 60 – 120 min in the onset of nausea and vomiting 
after spinal administration of Neostigmine.(105) This adverse effect is probably 
caused by the migration of neostigmine to the brain stem, because the nausea 
and vomiting did not occur until 63 – 115 min after spinal drug 
administration. None of the patient had abdominal cramps 
In our study, we selected relatively low doses of neostigmine (50 and 
100 µg) in hyperbaric bupivacaine solution and we maintained the patient in a 
head-up posture after the injection of the hyperbaric solution, in order to 
decrease the prevalence of adverse effects. In agreement with Hood's and Tan 
observations, metoclopramide used in our study was ineffective in stopping 
the nausea or vomiting. Three of five patients (60%) in group II and three of 
four patients (75%) in group III failed to respond to metoclopramide, and 
needed supplementation by another antiemetic agent, intravenous 
Ondansetron (4mg). Previous studies have reported similar difficulty in 
preventing or treating nausea and vomiting with spinal Neostigmine. 
Intrathecal neostigmine can cause motor weakness of lower extremities 
in animals and humans volunteers by an ACH-mediated reduction in the 
motor neuron outflow. The addition of 50 µg neostigmine prolonged motor 
block from bupivacaine anaesthesia.  In our study, the motor block produced 
 by intrathecal bupivacaine was greatly prolonged by the addition of 100 µg 
neostigmine. The duration of motor block increased from 4.8 ± 1.9 h with 50 
µg neostigmine to 5.8 ± 1.6 h with a dosage of 100 µg neostigmine compared 
to the non-neostigmine group, 4.37 ± 1.5 hours. 
Neostigmine-enhanced motor block from spinal local anaesthetics may 
be useful in some kinds of surgery, e.g. lower extremity surgical procedures 
requiring muscle relaxation. 
Respiratory depression and pruritus ascribed to use of spinal opioids 
were not encountered with spinal neostigmine. There was no significant 
alteration in BP and heart rate in any of the patients. This is consistent with 
the work of other investigators, on the used of spinal neostigmine in human. 
(106) Urinary retention has been observed with spinal intrathecal neostigmine, 
albeit the duration of urinary retention is brief compared with spinal 
morphine. We could not evaluate this parameter, in this study, as most of the 
patients were catheterized in the postoperative period. 
One patient from group II (5%) and another patient from group III (5%) 
had intraoperative bowel movement 150 min and 120 min, respectively, after 
the spinal injection. However, this adverse effect has been reported by 
Gabriela et al. study. 
In our study, dizziness, sedation and anxiety were not observed in 
patients  received  intrathecal neostigmine,  as was  reported by Hood's et al. 
in patients receiving 750 µg dose, and this can be explained by the smaller 
dose (50 – 100 µg) used in our study.(79)  
 
 
 
 
 CONCLUSIONS 
 
• Addition of neostigmine improves the onset of bupivacaine, as measured 
by the level of sensory block and this reveals an additive effect of the 
combined administration of intrathecal neostigmine and bupivacaine. 
• In patients undergoing infra-umbilical surgery, intrathecal neostigmine 
administered at 50 µg or 100 µg enhances the effects of bupivacaine 
anaesthesia and provides dose-dependent analgesia for a period of about 
4.5 – 7.5 hours. 
• Spinal neostigmine prolongs the duration of motor block from bupivacaine 
anaesthesia, which may be useful in some kinds of surgery. On the other 
hand, this can limit its use for day case surgery.  
• This anaesthetics mixture, however, especially that containing neostigmine 
at 100 µg, causes a significant increase in adverse effects, such as nausea 
and vomiting, and prolongs motor block, which may restrict the usefulness 
of intrathecal neostigmine as a sole analgesic agent. 
• A part from nausea and vomiting, this regimen of spinal neostigmine and 
bupivacaine is not associated with any serious side effects. 
• Metoclopramide, used in our study, is effective in decreasing the severity 
of nausea but is ineffective in stopping vomiting when compared with the 
effectiveness of Ondansetron. 
• The technique is simple, instruments needed are readily available and no 
special drug preparation is needed (as it is safe to use neostigmine with 
preservative). 
 
 
 
 RECOMMENDATIONS 
As has been demonstrated by this, and previous, studies intrathecal 
neostigmine could produce a dose-dependent analgesia and a dose-dependent 
adverse effect. Therefore, efforts can be made to reduce the undesirable 
adverse effects of intrathecal neostigmine to be clinically useful, we 
recommend:- 
•  Minimization of cephalic spread, which is blamed for the increases 
incidence of nausea and vomiting. The mixture of neostigmine with 
hyperbaric dextrose solution of spinal anaesthetic is advocated. 
• Probably the epidural route of administration of neostigmine is minimizing 
cephalic spread and may eventually prove superior to the intrathecal route 
with respect to the incidence of associated nausea and vomiting. 
• A mixture of spinal Neostigmine, opioids, and local anaesthetic, can 
increase the duration of analgesia, and reduce the postoperative analgesic 
demand without increasing the incidence of adverse effects. As the mass 
of each agent will be decreased. 
• Prophylactic administration of the antiemetic agent, ondansetron, may 
be more effective than treatment, for prevention of intra- and postoperative 
nausea and vomiting. 
• Because the better quality of analgesia increases the incidence of untoward 
side effects, a larger sample should be studied before this application can 
be routinely used clinically. 
• Regional anaesthesia for caesarean section, whether urgent or elective, has 
become the anaesthetic technique of choice. In previous studies, 
Intrathecal neostigmine did not affect fetal heart rate tracing or apgar 
scores in women prior to cesarean section and was well tolerated. 
Intrathecal neostigmine was associated with reduced postoperative 
morphine requirements with a trend toward blunting of lidocaine-induced 
 hypotension. These findings support further clinical investigation of 
intrathecal neostigmine in obstetrics. 
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 ﻢﻴﺣﺮﻟا ﻦﻤﺣﺮﻟا ﷲﺎﻤﺴﺑ 
 
 
 
Date: / /         Patient number ( )  
 
Name: …………………………………………………………. 
Age:    (22-70y) ( y) 
Sex:    (M) (F) 
Place (KTH)   (SUH) Ward: ………………………….. 
 
Kind of surgery:  
Surgery duration:  min 
 
History: 
? Any systemic disease(Y) (N)………………………………… 
.................................................................................................... 
? Presence of preoperative nausea or vomiting (Y) (N) 
? Any premeditation (Y) (N) 
? Written informed consent (Y) (N) 
? Any CI to spinal anaesthesia (Y) (N) 
 
Examination finding:  
 
Preload 500 ml – normal saline 0.9 (Y) (N) 
Intra-operative total fluids (   ml) 
 
Test drug given: 
? Group1 (bupivacaine 15mg + 0.5ml D5%)        ( ) 
? Group2 (bupivacaine 15mg+0.5ml neostigmine 50µg)   (   ) 
? Group3 (bupivacaine 15mg+0.5ml neostigmine100µg)  ( ) 
 
 
 
 
 
 
 
ASA physical status (1) (2) 
 
Time of start of anaesthesia ( ) 
 
Time of start of operation      ( ) 
Time of end of operation       ( ) 
 
Sensory level at: 
? 5 minutes  ( ) 
? 10minutes ( ) 
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Note: 
? atropine 0.5mg IV if PR ≤ 60 beats/min 
? ephedrine 5 -10mg IV if systolic BP ≤ 100 mmHg 
? nausea (VAS) >2                 
                                                                       Metoclopramide 10 mg i.v.   
? vomiting > once   
? Diclofenac 75mg IM if pain score ≥ 4 (repeated 8 hourly if 
necessary). 
? Objective score of sedation based on eye opening: 
? Eyes opening spontaneously = 0 
? Eyes opening in response to speech = 1 
? Eyes opening in response to physical stimulation = 2 
? Bromage motor scale: 
? No block (1) (the ability to flex the knees and feet) 
? Partial block (2) (ability to flex the knees and resist gravity with full 
movement at the feet) 
? Almost complete block (3) (inability to flex the knees but retain the 
ability to flex the feet) 
? Complete block (4) (in ability to flex the legs or feet). 
 
 
